P2 - Poster Session II

Event Time:	Monday April 23, 2018 11:30 am to 7:00 pm
Topic(s):	Aging, Dementia, Cognitive, and Behavioral Neurology, Cerebrovascular Disease and Interventional Neurology, Child Neurology and Developmental Neurology, Epilepsy/Clinical Neurophysiology (EEG), Movement Disorders, MS and CNS Inflammatory Disease, Neuromuscular and Clinical Neurophysiology (EMG), Neuro-ophthalmology/Neuro-otology, Pain and Palliative Care, Research Methodology, Education, and History
Director(s):
Description:	A series of thematic abstract presentations in poster format presented Sunday through Friday with evening stand-by times for authors. The specific stand-by time for this session is 5:30 p.m. to 7:00 p.m.
Completion Message:
CME Credits:	0
Core Competencies:

Program Speakers - Tentative
Start/End Time	Title	Faculty
11:45 AM - 11:50 AM	P2.027	Faculty
11:50 AM - 11:55 AM	P2.028	Faculty
11:55 AM - 12:00 PM	P2.029	Faculty
12:00 PM - 12:05 PM	P2.030	Faculty
12:05 PM - 12:10 PM	P2.031	Faculty
12:10 PM - 12:15 PM	P2.032	Faculty
12:15 PM - 12:20 PM	P2.033	Faculty
12:20 PM - 12:25 PM	P2.034	Faculty
12:25 PM - 12:30 PM	P2.035	Faculty
12:30 PM - 12:35 PM	P2.036	Faculty
5:30 PM - 7:00 PM	Poster Author Standby Time	Faculty

Disclosures
Speaker	Disclosure

Abstract Presenters
Undergraduate Medical Education: Assessment and Curricular Design I
Start Time	Pub.	Title	Presenter
5:30 PM	001	Common difficulties medical students have with the neurological physical exam are identified by direct observation.	Juliana Coleman, MD Disclosure: Dr. Coleman has nothing to disclose.
5:30 PM	002	Evaluation of a Single Year Competency-Based Clerkship Alternative to Effectively Navigate a Fourth-Year to Third Year Curricular Transition	Jeff Kraakevik, MD Disclosure: Dr. Kraakevik has nothing to disclose.
5:30 PM	003	Developing a Student-Centric/Student Responsive Four Week Neurology Clerkship	Raghav Govindarajan, MD, FAAN Disclosure: Dr. Govindarajan has nothing to disclose.
5:30 PM	004	Published Headache OSCEs Have Excellent Inter-rater Reliability	Maryam Shakir, MPH Disclosure: Dr. Shakir has received research support from American Academy of Neurology Education Research Grant.
5:30 PM	005	Why aren't you giving feedback?	Doris Kung, DO Disclosure: Dr. Kung has nothing to disclose.
Undergraduate Medical Education: Novel Formats
Start Time	Pub.	Title	Presenter
5:30 PM	006	Movement Disorders Video Curriculum for Neurology Clerkships and Residency Programs	Sagari Bette, MD Disclosure: Dr. Bette has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck.
5:30 PM	007	Assessment Of The Difficult Components Of Neurological Exam Performance In Medical Students	Yi Li, MD Disclosure: Dr. Li has nothing to disclose.
5:30 PM	008	Animated Neurological Exam Videos in PBL Cases	J. Douglas Miles, MD, PhD Disclosure: Dr. Miles has nothing to disclose.
5:30 PM	009	Student Neurology Clerkship Improvement Project ("SNIP")	Victoria Cannon, MD Disclosure: Dr. Cannon has nothing to disclose.
5:30 PM	010	Incorporating Formal Nutrition Education into a Medical School Curriculum: A Student-Initiated Lecture Series	Vanessa Baute, MD Disclosure: Dr. Baute has nothing to disclose.
5:30 PM	011	Expert Patient Tutors: The Eradication of Neurophobia	Gina Hadley, MD Disclosure: Dr. Hadley has nothing to disclose.
Health Services Research and Methodologies
Start Time	Pub.	Title	Presenter
5:30 PM	012	Common Data Elements (CDEs) for Biomechanical Devices used in Blunt Head Impact and Blast Exposure Dynamics: The National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and Department of Defense (DOD) Version 1.0 Recommendations	Kristen Joseph, MA Disclosure: Dr. Joseph has nothing to disclose.
5:30 PM	013	Development of diagnostic criteria to facilitate research in mitochondrial disorders: a proposal from the North American Mitochondrial Disease Consortium.	Valentina Emmanuele, MD Disclosure: Dr. Emmanuele has nothing to disclose.
5:30 PM	014	Streamlining Clinical Research in Sports-Related Concussion: The National Institute of Neurological Disorders and Stroke (NINDS)/National Institutes of Health (NIH), and Department of Defense (DOD) Sport-Related Concussion Common Data Elements (CDEs)	Kristen Joseph, MA Disclosure: Dr. Joseph has nothing to disclose.
5:30 PM	015	Registration status of clinical trials published in core neurology journals: a cross-sectional study	Jose Merino, MD, MPhil, FAAN Disclosure: Dr. Merino has received personal compensation in an editorial capacity for US Research Editor for The BMJ.
5:30 PM	016	A Common Language for Clinical Research Studies: The National Institute of Neurological Disorders and Stroke (NINDS) and Centers for Disease Control and Prevention (CDC) Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Common Data Elements (CDEs)	Robin Feldman Disclosure: Dr. Feldman has nothing to disclose.
Education: Career Choice and Attitudes
Start Time	Pub.	Title	Presenter
5:30 PM	017	Headache interest in US academic neurology leadership: a cross-sectional study	Matthew Robbins, MD, FAAN Disclosure: Dr. Robbins has received personal compensation in an editorial capacity for Springer (Current Pain and Headache Reports).
5:30 PM	018	Neurology Residency Websites: A Critical Evaluation.	Adeel Memon Disclosure: Dr. Memon has nothing to disclose.
5:30 PM	019	The Rutgers-NJMS Experience: Why Are Our Medical Students Increasingly Applying to Adult Neurology?	Jessy Walia, MBBS Disclosure: Dr. Walia has nothing to disclose.
5:30 PM	020	Changing the Image of Neurology	Yolanda Reyes-Iglesias, MD Disclosure: Dr. Reyes-Iglesias has nothing to disclose.
5:30 PM	021	The Importance of Neurology as a Required Third-Year Clerkship: a Medical Student Survey	Enmanuel Perez Disclosure: Dr. Perez has nothing to disclose.
5:30 PM	022	The Impact of Early Medical School Exposure to Clinical Neurology on Career Interest in Neurology	Yasmin Aghajan Disclosure: Dr. Aghajan has nothing to disclose.
5:30 PM	023	NA	NA NA Disclosure:
5:30 PM	024	NA	NA NA Disclosure:
5:30 PM	025	NA	NA NA Disclosure:
5:30 PM	026	NA	NA NA Disclosure:
Neuromuscular and Clinical Neurophysiology (EMG) Poster Discussion Session
Start Time	Pub.	Title	Presenter
5:30 PM	027	Machine-learning in neurodegeneration: evaluation, optimisation and validation of MRI-based diagnostic methods	Peter Bede, MD Disclosure: Dr. Bede has nothing to disclose.
5:30 PM	028	Skeletal Muscle Interstitial Amyloid in Anoctaminopathy-5: Does it Matter?	Charenya Anandan, MD Disclosure: Dr. Anandan has nothing to disclose.
5:30 PM	029	Egr2-dependent microRNA-138 is Dispensable for Peripheral Nerve Myelination	Hsin-Pin Lin Disclosure: Dr. Lin has nothing to disclose.
5:30 PM	030	The Long Exercise Test in Primary Periodic Paralysis: a Bayesian Analysis	Daniel Simmons, MD Disclosure: Dr. Simmons has nothing to disclose.
5:30 PM	031	Congenital Myasthenic Syndromes (CMS) Due to Impaired Principal Coupling Pathway in the ? Subunit of Muscle Acetylcholine Receptor (AChR)	Xin-Ming Shen, PhD Disclosure: Dr. Shen has nothing to disclose.
5:30 PM	032	Integrated MRI and [11C]-PBR28 PET Imaging to Characterize In vivo Glial Activation in Amyotrophic and Primary Lateral Sclerosis: Cross Sectional and Longitudinal Study	Mohamad Alshikho Disclosure: Dr. Alshikho has nothing to disclose.
5:30 PM	033	Undiagnosed Congenital Myasthenic Syndromes in Adult Neuromuscular Practice: a Long Road to Diagnosis and Treatment.	Justin Kao, MBChB Disclosure: Dr. Kao has nothing to disclose.
5:30 PM	034	ALS progression over short time intervals: early insights from the ongoing ALS-at-home study	Seward Rutkove, MD Disclosure: Dr. Rutkove has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Myolex, Biogen, Axcella Health, Merck. Dr. Rutkove has received personal compensation in an editorial capacity for Annals of Neurology. Dr. Rutkove has received compensation for serving on the Board of Directors of Myolex, Inc. Dr. Rutkove holds stock and/or stock options in Myolex, Inc which sponsored research in which Dr. Rutkove was involved as an investigator. . Dr. Rutkove holds stock and/or stock options in Myolex, Inc. Dr. Rutkove has received research support from Flex-Pharma, Inc.
5:30 PM	035	Efficacy of Dichlorphenamide in Primary Periodic Paralysis: Pooled-Data Analysis of Two Phase 3 Clinical Trials	Perry Shieh, MD, PhD Disclosure: Dr. Shieh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion; AveXis, Inc.; Biogen; Grifols; PTC; Sarepta. Dr. Shieh has received research support from AveXis, Inc.; Audentes; Biogen; Bristol-Myers Squibb; Cytokinetics; Catalyst; Fibrogen; Ionis Pharmaceuticals, Inc.; Marathon; Pfizer; PTC; Sarepta; Santhera; Summit; Sanofi/Genzyme; Ultragenyx.
5:30 PM	036	Decreased EEG Spectral Power and Increased Cortico-Cortical Connectivity Correlate with Structural MRI Changes in Amyotrophic Lateral Sclerosis	Stefan Dukic Disclosure: Dr. Dukic has nothing to disclose.
Parkinson's Disease: Therapeutics
Start Time	Pub.	Title	Presenter
5:30 PM	037	Effects of Probiotics on Constipation, Neurological Symptoms, and Quality of Life Associated with Parkinson's Disease	Duarte Machado, MD Disclosure: Dr. Machado has nothing to disclose.
5:30 PM	038	Exploratory risk analysis for motor complications and non-motor symptoms: observations in a registry of a tertiary Parkinson's disease center in Brasilia, Brazil	Talyta Grippe, MD Disclosure: Dr. Grippe has nothing to disclose.
5:30 PM	039	A Phase 2 study of Isradipine as a disease modifying agent in patients with early Parkinson's disease (STEADY-PD III): Baseline characteristics and study update	Tanya Simuni, MD Disclosure: Dr. Simuni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acadia, Adamas, Teva, UCB Pharma, Abbvie, Anavex, Allergan, Accorda, Neuroderm, Photopharmics, Revance, Sanofi, Sunovion, Voyager, US World Meds, and the Michael J. Fox Foundation. Dr. Simuni has received research support from Biogen, Roche, Neuroderm, Sanofi, NINDS, the Michael J. Fox Foundation, and the Parkinson Foundation.
5:30 PM	040	Optimizing Delivery of Carbidopa/Levodopa via the Accordion Pill™: Comparative PK and Safety From 2 Randomized Crossover Studies in Healthy Volunteers	Nadav Navon Disclosure: Dr. Navon has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with N Navon is employed by Intec Pharma. .
5:30 PM	041	Objective Evaluation of Levodopa Response on Gait and Balance	Alexandra Fowler Disclosure: Dr. Fowler has nothing to disclose.
5:30 PM	042	Effect of PD medication on disease progression as measured by rate of change in MDS_UPDRS in PPMI study	Zhen Xiao, PhD Disclosure: Dr. Xiao has nothing to disclose.
5:30 PM	043	Pharmacokinetics of ADS-5102 (amantadine) Extended Release Capsules Administered Once-Daily at Bedtime for the Treatment of Dyskinesia	Robert Hauser, MD, MBA, FAAN Disclosure: Dr. Hauser has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Robert A. Hauser reports consulting fees from: AbbVie Inc., Acorda Therapeutics, Academy for Continued Healthcare Learning, Acadia Pharmaceuticals, Inc., Adamas Pharmaceuticals, AstraZeneca, ApoPharma, Back Bay Life Science, Biotie Therapies, Bracket, Cerecor, Inc., ClearView Healthcare Partners, ClinicalMind Medical and Therapeutic Communications, CNS Ratings, LLC., Cowen and Company, Cynapsus Therapeutics, DDB Health LLC, Decision Resources Group (DRG), Eli Lilly & Company, eResearch Technology, Inc., Expert Connect, Extera Partners, GE Healthcare, Health Advances, HealthLogix, Health and Wellness Partners, Huron Consulting Group, Impax Laboratories, Impel Neuropharma, Intec Pharma Ltd., Jazz Pharmaceuticals, Kashiv Pharma LLC, Kyowa Kirin Pharmaceutical Development, Ltd., LCN Consulting, LifeMax, Life Sciences, Lundbeck LLC, The Lockwood Group, MEDACorp, Medscape, Medtronic, Michael J. Fox Foundation, Mitsubishi Tanabe Pharmaceuticals, Movement Disorder Society, National Institutes of Health (NIH), Neurocea LLC, Neurocrine Biosciences, Neuroderm, Neuropore Therapies, Orbes Medical Group, Outcomes Insights, Parkinson Study Group, Peerview Press, Pennside Partners, Pfizer, Inc., Pharma Two B, Ltd, Phase Five Communications, Prescott Medical Group, Prexton Therapeutics, Prilenia Development Ltd., Projects in Knowledge, Putnam Associates, Quintiles, RMEI Medical Education for Better Outcomes, SAI Med Partners LLC, Sarepta Therapeutics, Schlesinger Associates, Scion Neurostim, LLC, Seagrove Partners, LLC, Slingshot Insights, Sunovion Pharmaceuticals, Inc., Sun Pharma, Teva Pharmaceutical Industries, US WorldMeds, Vista Research, WebMD, Windrose Consulting Group.. Dr. Hauser has received royalty, license fees, or contractual rights payments from Dr. Hauser reports receiving licensing fee payments from the University of South Florida.. Dr. Hauser has received research support from Dr. Hauser reports research support from: AbbVie Inc., Acorda Therapeutics, AstraZeneca, Axovant Sciences , Biogen Inc., Cavion, Enterin Inc., Impax Laboratories, LLC., Intec Pharma Ltd, Jazz Pharmaceuticals, NeuroDerm Ltd., Lundbeck, Michael J Fox Foundation for Parkinson’s Research, F. Hoffman-La Roche, Dart NeuroScience LLC, Prexton Therapeutics, Revance Therapeutics Inc., Sunovion Pharmaceuticals. Dr. Hauser reports grant support from: Parkinson’s Foundation..
5:30 PM	044	The iNDiGO study: A multicenter, randomized, double-blind, placebo-controlled clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in fluctuating PD	Karl Kieburtz, MD, FAAN Disclosure: Dr. Kieburtz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with K. Kieburtz has consulted with Acorda, Aptinyx, Astellas Pharma, AstraZeneca, BioMarin, Biotie, Blackthorn, Britannia, Centrexion, CHDI, Clintrex, Concert, Cynapsus, DART, Denali, EMD Serono, Dart Neuroscience, Forward Pharma, Genzyme, INC Research, Inhibikase, Intec, Ipsen, Jazz, Knopp, Kyowa Kirin, Lundbeck, Medivation, Melior Discovery, Medgenesis, Monosol, Neurocrine, Neuroderm, Neuropore, Orion Pharma, Otsuka, Pfizer, Pharma2B, Photopharmics, Prana Biotechnology, Prothena/Neotope/Elan Pharmaceutical, PTC, Raptor Pharmaceuticals, Remedy Pharmaceuticals, Roche/Genentech, Sage Bionetworks, Sanofi, Sarepta, Serina, Sunovion, Synagile, Teva, UCB Pharma, Ultragenyx, Uniqure, US WorldMeds, Vaccinex, vTv Therapeutics, Voyager, and Weston Brain Institute. . Dr. Kieburtz has received research support from K. Kieburtz has received research grant support from the National Institutes of Health (NINDS) and the Michael J Fox Foundation..
5:30 PM	045	A Phase 3 Study of Tozadenant (TOZ-PD) as a Maintenance Therapy for Patients With Parkinson's Disease Experiencing Motor Fluctuations: Characterization of Study Population	Karl Kieburtz Disclosure: Dr. Kieburtz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with K. Kieburtz has consulted with Acorda, Aptinyx, Astellas Pharma, AstraZeneca, BioMarin, Biotie, Blackthorn, Britannia, Centrexion, CHDI, Clintrex, Concert, Cynapsus, DART, Denali, EMD Serono, Dart Neuroscience, Forward Pharma, Genzyme, INC Research, Inhibikase, Intec, Ipsen, Jazz, Knopp, Kyowa Kirin, Lundbeck, Medivation, Melior Discovery, Medgenesis, Monosol, Neurocrine, Neuroderm, Neuropore, Orion Pharma, Otsuka, Pfizer, Pharma2B, Photopharmics, Prana Biotechnology, Prothena/Neotope/Elan Pharmaceutical, PTC, Raptor Pharmaceuticals, Remedy Pharmaceuticals, Roche/Genentech, Sage Bionetworks, Sanofi, Sarepta, Serina, Sunovion, Synagile, Teva, UCB Pharma, Ultragenyx, Uniqure, US WorldMeds, Vaccinex, vTv Therapeutics, Voyager, and Weston Brain Institute. . Dr. Kieburtz has received research support from K. Kieburtz has received research grant support from the National Institutes of Health (NINDS) and the Michael J Fox Foundation..
5:30 PM	046	Safety and Efficacy of Levodopa-Carbidopa Monotherapy in Patients with Advanced Parkinson's Disease	James Boyd, MD Disclosure: Dr. Boyd has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc., Teva, Lundbeck, Chrono Therapeutics, Neurocrine and Medical Education Resources. Dr. Boyd has received research support from Michael J. Fox Foundation, NIH/NINDS, Auspex, Biotie, CHDI Foundation, NeuroDerm, Chrono Therapeutics, Vaccinex, AbbVie Inc.
5:30 PM	047	Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Advanced Parkinson's Disease Patients Receiving ≥ 2000 mg Daily Dose of Levodopa	Cindy Zadikoff, MD Disclosure: Dr. Zadikoff has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, USworldMeds, Acadia, UCB, St Jude, Merz, Teva, Lundbeck. Dr. Zadikoff holds stock and/or stock options in Dial N Doc. Dr. Zadikoff has received research support from AbbVie, Allergan, and St Jude for unrestricted educational grants.
5:30 PM	048	Rationale and Design of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson's Disease - INSIGHTS Study	K. Ray Chaudhuri Disclosure: Dr. Chaudhuri has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB, AbbVie, Britannia, Mundipharma, Boehringer Ingelheim, GSK Pharmaceuticals, Neuronova. Dr. Chaudhuri has received royalty, license fees, or contractual rights payments from King’s Parkinson’s Pain Scale and Parkinson’s Disease Sleep Scale. Dr. Chaudhuri has received research support from AbbVie Inc.
Parkinson's Disease: Phenomenology, Epidemiology and Rating Scales
Start Time	Pub.	Title	Presenter
5:30 PM	049	Dry facts are not always inviting: an analysis of Korean videos about Parkinson's disease on YouTube	Beomseok Jeon, MD Disclosure: Dr. Jeon has nothing to disclose.
5:30 PM	050	Clinical factors associated with clinician certainty in diagnosis of idiopathic Parkinson's disease	Kishan Ughreja, BA Disclosure: Dr. Ughreja has nothing to disclose.
5:30 PM	051	Item Response Theory Analysis of the Unified Dyskinesia Rating Scale Items	Christopher Goetz, MD, FAAN Disclosure: Dr. Goetz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consulting or Advisory Board Membership with honoraria: Boston Scientific: Presidential stipend from the International Parkinson and Movement Disorder Society paid to Rush University Medical Center as part of Dr. Goetz’s salary. Faculty stipend from the International Parkinson and Movement Disorder Society. Legal deposition payment received from Cray-Huber Attorneys. Lecture honorarium from the University of Pittsburgh. Salary: Rush University Medical Center. Dr. Goetz has received royalty, license fees, or contractual rights payments from Royalties: Elsevier Publishers, Oxford University Press, Wolters Kluwer. Dr. Goetz has received research support from Grants/Research: Funding to Rush University Medical Center from NIH, Michael J. Fox Foundation for research conducted by Dr. Goetz. Dr. Goetz directs the Rush Parkinson’s Disease Research Center that receives support from the Parkinson’s Disease Foundation and some of these funds support Dr. Goetz's salary as well as his research efforts. He directed the translation program for the MDS-UPDRS and UDysRS and received funds directed to Rush University Medical Center from the International Parkinson and Movement Disorder Society (IPMDS) for this effort.
5:30 PM	052	A Clinically Important Difference (CID) for the Unified Dyskinesia Rating Scale (UDysRS) Total Score Change in Parkinson's Disease (PD) Patients with Dyskinesia	Rajesh Pahwa, MD, FAAN Disclosure: Dr. Pahwa has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, ACADIA, Acorda, Adamas, Cynapsus, Global Kinetics, Ionis, Lundbeck, Neurocrine Biosciences, St. Jude Medical, Sunovion, Teva Neuroscience, UCB and US World Meds. Received research grants from Abbott, AbbVie, Acorda, Adamas, BMS, Boston Scientific, Cala Health, Cavion, Cynapsus, Intec, Jazz, Kyowa, Lilly, National Parkinson Foundation, NIH/NINDS, Parkinson Study Group, Pfizer, Prexton, Roche, Sunovion and US WorldMeds.. Dr. Pahwa has received personal compensation in an editorial capacity for Abbvie, ACADIA, Acorda, Adamas, Cynapsus, Global Kinetics, Ionis, Lundbeck, Neurocrine Biosciences, St. Jude Medical, Sunovion, Teva Neuroscience, UCB and US World Meds. Received research grants from Abbott, AbbVie, Acorda, Adamas, BMS, Boston Scientific, Cala Health, Cavion, Cynapsus, Intec, Jazz, Kyowa, Lilly, National Parkinson Foundation, NIH/NINDS, Parkinson Study Group, Pfizer, Prexton, Roche, Sunovion and US WorldMeds.. Dr. Pahwa has received research support from Abbvie, ACADIA, Acorda, Adamas, Cynapsus, Global Kinetics, Ionis, Lundbeck, Neurocrine Biosciences, St. Jude Medical, Sunovion, Teva Neuroscience, UCB and US World Meds. Received research grants from Abbott, AbbVie, Acorda, Adamas, BMS, Boston Scientific, Cala Health, Cavion, Cynapsus, Intec, Jazz, Kyowa, Lilly, National Parkinson Foundation, NIH/NINDS, Parkinson Study Group, Pfizer, Prexton, Roche, Sunovion and US WorldMeds..
5:30 PM	053	Smoking and Coffee Consumption Preceding Clinically-diagnosed Synucleinopathies: A Case-control Study in Olmsted County MN (1991-2005).	Jinna Yu Disclosure: Dr. Yu has nothing to disclose.
5:30 PM	054	Predictors of Disability in Parkinson Disease: Motor vs. Cognitive Impairment Using MMSE vs. MoCA	Allison Snyder, MD Disclosure: Dr. Snyder has nothing to disclose.
5:30 PM	055	Communication Regarding Off Time with People with Parkinsons and their Caregivers: Qualitative Analysis of Physician Interviews	Tara Rastgardani, MD Disclosure: Dr. Rastgardani has nothing to disclose.
5:30 PM	056	Foundations for a Patient-Reported Natural History of Parkinson Disease: Cross-sectional Analysis of the MJFF Fox Insight (FI) Platform	Lakshmi Arbatti Disclosure: Dr. Arbatti has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Grey Matter Technologies.
5:30 PM	057	Stumbling, Near-falls, Freezing or Postural Instability: What Predicts Falling Best in Parkinson Disease?	Zahra Nooshin Rezvani Disclosure: Dr. Rezvani has nothing to disclose.
5:30 PM	058	Diagnostic Impact of Movement Disorders Subspecialty Consultations at a VA Hospital	Brandon Barton, MD Disclosure: Dr. Barton has nothing to disclose.
5:30 PM	059	Levodopa-induced dyskinesias in Parkinson disease: a population based-cohort study in Olmsted County, MN (1991-2010)	Pierpaolo Turcano, MD Disclosure: Dr. Turcano has nothing to disclose.
5:30 PM	060	A Real-World Inquiry of the So-Called Parkinsonian Personality -- Comparing No-Show Rates of the Neurology Outpatients with and without Parkinson's disease (PD)	Jeremiah Bell, MD Disclosure: Dr. Bell has nothing to disclose.
5:30 PM	061	Parkinson's Diagnostic Accuracy- What diagnoses cause the most diagnostic-switches by Movement Disorder Specialists?	Marzieh Keshtkarjahromi Disclosure: Dr. Keshtkarjahromi has nothing to disclose.
5:30 PM	062	Barriers to Vaccination in Homebound and Non-Homebound People with Parkinson's Disease	Jori Fleisher, MD, MSCE Disclosure: Dr. Fleisher has received research support from Biogen.
5:30 PM	063	Traumatic brain injury and erectile dysfunction preceding clinically diagnosed alpha-synucleinopathies: a case - control study in Olmsted County, MN (1991-2010).	Shemonti Hasan Disclosure: Dr. Hasan has nothing to disclose.
5:30 PM	064	Objective Markers of Turning in Idiopathic Parkinson's Disease	Lakshmi Pillai Disclosure: Dr. Pillai has nothing to disclose.
5:30 PM	066	Prevalence and patterns of rest, postural and action tremor in drug-naive Parkinson's disease	Deepak Gupta, MD, MBBS Disclosure: Dr. Gupta has nothing to disclose.
5:30 PM	067	Experiences, impact, and communication of "off" periods in Parkinson's disease: qualitative experiences of patients and carepartners	Tara Rastgardani, MD Disclosure: Dr. Rastgardani has nothing to disclose.
5:30 PM	068	Characteristics of Patients with Parkinson Disease in Pakistan: Prospective Multicenter Cross-sectional Study	Wagma Shahzad Disclosure: Dr. Shahzad has nothing to disclose.
5:30 PM	069	Predictors of health-related quality of life in Parkinson's disease	Gregory Kuhlman, MD Disclosure: Dr. Kuhlman has nothing to disclose.
5:30 PM	070	Prenatal Exposure to Chlorpyrifos and Parkinson's risk: a prospective adolescent cohort evaluation	Sarah O'Shea, MD Disclosure: Dr. O'Shea has nothing to disclose.
5:30 PM	071	Primary Care Knowledge and Referral Practices Based on Early Symptoms of Parkinson's Disease	Stephanie Bissonnette, DO Disclosure: Dr. Bissonnette has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Intec, Biogen and Pharma2B; Consultant for Delsys. .
5:30 PM	072	Characterizing Types of Falls in Parkinson's Disease	Abraham Lieberman, MD, FAAN Disclosure: Dr. Lieberman has nothing to disclose.
5:30 PM	073	Healthcare Disparities in African-American Patients with Parkinson's Disease : A Comprehensive Literature Review and Call to Action	Shivani Naik Disclosure: Dr. Naik has nothing to disclose.
5:30 PM	074	Deeply Phenotyped Control Cohort for Studies of Parkinson's Disease	Rana Hanna AL-Shaikh Disclosure: Dr. Hanna AL-Shaikh has nothing to disclose.
5:30 PM	075	The Prevalence of Tandem Gait Abnormality in Parkinson's Disease	Jason Margolesky, MD Disclosure: Dr. Margolesky has nothing to disclose.
5:30 PM	076	Instructed Arm Swing Improves Walking Performance and Decreases Fall Risk in Individuals with Parkinsonism	Evan Fitzgerald Disclosure: Mr. Fitzgerald has nothing to disclose.
5:30 PM	077	Development of a Parkinson's Disease-Specific Admission Order Set	Danielle Larson, MD Disclosure: Dr. Larson has nothing to disclose.
5:30 PM	078	Sex Disparities in Health and Health Care Utilization after Parkinson Diagnosis: Rethinking PD Associated Disability	Michelle Fullard, MD Disclosure: Dr. Fullard has nothing to disclose.
5:30 PM	079	Characterization of variants in genes associated with Parkinson´s disease and parkinsonism in the African American population using exome sequencing	Angela Deutschlander, MD Disclosure: Dr. Deutschlander has received research support from Allergan, Inc.
5:30 PM	080	Presentation of Parkinson's disease in patients originating of different geographical altitudes	Kelly Meza Capcha Disclosure: Dr. Meza Capcha has nothing to disclose.
5:30 PM	081	Differences in Quality of Life Between Men and Women with Parkinson's Disease	Medha Gudavalli Disclosure: Dr. Gudavalli has nothing to disclose.
5:30 PM	082	Predictors of Clinically Meaningful Change in PDQ-39 in Parkinson's Disease	Adam Margolius, MD Disclosure: Dr. Margolius has nothing to disclose.
5:30 PM	083	Use of a modified STROOP test to help with diagnosis in early idiopathic Parkinson's disease	Rebekah Langston Disclosure: Dr. Langston has nothing to disclose.
5:30 PM	084	NA	NA NA Disclosure:
Child Neurology and Developmental Neurology ePoster Session
Start Time	Pub.	Title	Presenter
5:30 PM	085	A splice-site mutation in USMG5 causes Leigh Syndrome due to lack of ATP synthesis	Emanuele Barca, MD Disclosure: Dr. Barca has nothing to disclose.
5:30 PM	086	Long-term Neurodevelopmental Outcomes in Preterm Infants with Posthemorrhagic Hydrocephalus Treated with Temporizing Devices	Lydia Bernhardt Disclosure: Dr. Bernhardt has nothing to disclose.
5:30 PM	087	Clinical profile and outcome of children with Lennox Gastaut Syndrome: Retrospective single centre cohort	Vishal Sondhi Disclosure: Dr. Sondhi has nothing to disclose.
5:30 PM	088	Iron and ferritin levels in patients with ADHD	Shreya Agarwal Disclosure: Dr. Agarwal has nothing to disclose.
5:30 PM	089	Unusual Presentation of Wilson Disease in a Pediatric Patient: Case Report	Michael DiSano, MD Disclosure: Dr. DiSano has nothing to disclose.
5:30 PM	090	Striatal Changes on MRI in Young Children with NMDAR: A Single Center Experience	Michael Nelson Disclosure: Dr. Nelson has nothing to disclose.
Pain and Palliative Care
Start Time	Pub.	Title	Presenter
5:30 PM	091	Gluten Neuropathy: Prevalence of Pain and the Role of Gluten-Free Diet.	Panagiotis Zis, MBBS, PhD Disclosure: Dr. Zis has nothing to disclose.
5:30 PM	093	ALS Patient Perspectives on Physician Assisted Death After Recent Passage of End of Life Options Act	Nicole Heinl Disclosure: Dr. Heinl has nothing to disclose.
5:30 PM	094	Prognostic Factors and Effectiveness of Percutaneous Balloon Compression in the Treatment of Trigeminal Neuralgia: An Experience of 222 patients	Sergio A. F. Dantas Disclosure: Dr. Adrian Fernandes Dantas has nothing to disclose.
5:30 PM	095	Evaluation of Pain Reproduction and other Predictive Factors of Selective Lumbar Nerve Block Efficacy for the Diagnosis and Palliative Treatment of Chronic Low Back Pain: A Retrospective Cohort Study	Yi Tong Disclosure: Dr. Tong has nothing to disclose.
5:30 PM	096	Widespread Myofascial Dysfunction and Regional Sensitization in Women with Endometriosis-associated Chronic Pelvic Pain	Barbara Karp, MD Disclosure: Dr. Karp has received research support from Allergan, Merz.
5:30 PM	098	Botulinum Toxin Treatment of Chronic Pelvic Pain in Women with Endometriosis	Barbara Karp, MD Disclosure: Dr. Karp has received research support from Allergan, Merz.
5:30 PM	099	Evaluation of Clinical Symptom and Signs Related to Histological and Functional Properties of Small Fiber Neuropathy in Diabetic Neuropathic Pain Patients	ISIN UNAL-CEVIK Disclosure: Dr. UNAL-CEVIK has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer Inc.
5:30 PM	100	Polarity-specific Modulation of Central Pain Processing by Transcranial Direct Current Stimulation	Steffen Naegel, MD Disclosure: Dr. Naegel has nothing to disclose.
5:30 PM	102	Biotin-deficiency in patients with fibromyalgia syndrome combined with small fiber pathology.	Walter Maier-Janson, MD Disclosure: Dr. Maier-Janson has nothing to disclose.
5:30 PM	103	'Triggers' for a Palliative Care Service for Patients with Spinocerebellar Ataxia Type 1.	Patama Gomutbutra, MD Disclosure: Dr. Gomutbutra has nothing to disclose.
5:30 PM	104	Evaluation of Berberin- a Nrf2 Activator, on Paclitaxel-Induced Neuropathic Pain Model in Rat	amitava chakrabarti, MD, MBBS Disclosure: Dr. Chakrabarti has nothing to disclose.
5:30 PM	105	The Effectiveness of Spinal Cord Stimulation (SCS) In Reduction of Oral Opioid Use	Derek Yuan, MD Disclosure: Dr. Yuan has nothing to disclose.
5:30 PM	106	Efficacy and Safety of Repetitive Transcranial Magnetic Stimulation for the Treatment of Fibromyalgia: An open label clinical trial	Levi H. Jales Jr. Disclosure: Dr. Higino Jales Junior has nothing to disclose.
5:30 PM	107	Successful Treatment of Refractory Trigeminal Neuralgia with Sphenopalatine Ganglion Block	Mohamed Binfalah Disclosure: Dr. Falah has nothing to disclose.
5:30 PM	108	Inflamed Brain: A Neuro-Palliative Approach	Justin Voorhees Disclosure: Dr. Voorhees has nothing to disclose.
Autonomic Disorders: Autonomic Neuropathies
Start Time	Pub.	Title	Presenter
5:30 PM	109	Autoimmune polyneuropathy with severe dysautonomia after ipilimumab treatment for melanoma	Kyle Kern, MD, MS Disclosure: Dr. Kern has nothing to disclose.
5:30 PM	110	A Case of Paraneoplastic Dysautonomia and Small Fiber Neuropathy	Jacob Didion, MD Disclosure: Dr. Didion has nothing to disclose.
5:30 PM	111	Diagnostic Utility of Sweat Gland Nerve Fiber Density in Small Fiber Neuropathy	Peter Novak, MD Disclosure: Dr. Novak has nothing to disclose.
5:30 PM	112	Dysautonomia in Charcot-Marie-Tooth Disease and Correlations with Patient-Reported Disability	Sindhu Ramchandren, MD Disclosure: Dr. Ramchandren has nothing to disclose.
5:30 PM	113	Small Fiber Neuropathy and Multiple Endocrinopathies with COX6A1 Gene Deletion	Glen Cook, MD Disclosure: Dr. Cook has nothing to disclose.
5:30 PM	114	Characterizing the spectrum of autonomic impairment in neurologic disorders with calcium channel antibodies	Julie Khoury, MD Disclosure: Dr. Khoury has nothing to disclose.
5:30 PM	115	Autonomic description in patients with very early TTR amyloidosis (Familial Amyloid Polyneuropathy).	Maria Alejandra Gonzalez Duarte, MD Disclosure: Dr. Gonzalez Duarte has nothing to disclose.
5:30 PM	116	The effect of vagal dysfunction on cytokine networks in HIV	Elizabeth Pedowitz, MD Disclosure: Dr. Pedowitz has nothing to disclose.
Autonomic Disorders: Other
Start Time	Pub.	Title	Presenter
5:30 PM	117	Healthcare Related Costs of Autonomic Disorders in MHS Beneficiaries	Agata Bogacki Disclosure: Dr. Bogacki has nothing to disclose.
5:30 PM	118	Progressive Multiple Sclerosis Patients Have a Higher Burden of Autonomic Dysfunction Compared to Relapsing Remitting Phenotype	Ivan Adamec Disclosure: Dr. Adamec has nothing to disclose.
5:30 PM	119	Psychosis in Multiple System Atrophy	Jose-Alberto Palma, MD, PhD Disclosure: Dr. Palma has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck and Biogen. Dr. Palma has received personal compensation in an editorial capacity for Clinical Autonomic Research.
5:30 PM	120	Long-term Fingolimod therapy increases sympathetic cardiovascular modulation	Ruihao Wang Disclosure: Dr. Wang has nothing to disclose.
5:30 PM	121	Cognitive impairment correlates with autonomic dysfunction in patients with a history of traumatic brain injury	Max J. Hilz, MD, PhD, FAAN Disclosure: Dr. Hilz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme. Dr. Hilz has received personal compensation in an editorial capacity for Autonomic Neuroscience: Basic and Clinical. Dr. Hilz has received research support from Novartis Pharma GmbH.
5:30 PM	122	Seasonal Hypothermia, Hypersomnolence, Encephalopathy, and Hypoventilation Following Hypothalamus Injury - A Case of Human Hibernation?	Leighton Mohl, MD Disclosure: Dr. Mohl has nothing to disclose.
5:30 PM	123	Three Shapiro Syndrome cases : diagnostic challenge of clinical spectrum of the spontaneous paroxysmal hypothermia syndrome	Rubens Salomao Disclosure: Dr. Salomão has nothing to disclose.
5:30 PM	124	Autonomic Dysfunction in Patients with Down Syndrome and Alzheimer Disease	Eric Huttler Disclosure: Dr. Huttler has nothing to disclose.
Autonomic Disorders: Orthostatic Hypotension and Orthostatic Intolerance
Start Time	Pub.	Title	Presenter
5:30 PM	125	Understanding the Symptoms of Neurogenic Orthostatic Hypotension: Results From a Survey of Patients and Caregivers	Satish R. Raj Disclosure: Dr. Raj has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consulting/Serving on Advisory Board: Lundbeck, GE Healthcare. Dr. Raj has received personal compensation in an editorial capacity for Associate Editor of Autonomic Neurosciences: Basic & Clinical. Dr. Raj has received research support from Research support from Dysautonomia International, a 501(c)3 non-profit (unrelated to this project)..
5:30 PM	126	Addressing Orthostatic Hypotension in Parkinson Disease Patients in a Neurology Resident Continuity Clinic	Elisabeth Golden, MD Disclosure: Dr. Golden has nothing to disclose.
5:30 PM	127	Neurogenic Orthostatic Hypotension Burden of Illness Patient and Caregiver Survey: Impact of Symptoms	Daniel O. Claassen Disclosure: Dr. Claassen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Neuroscience, Lundbeck, Acadia, AbbVie. Dr. Claassen has received research support from NIH/NINDS, Michael J. Fox Foundation, Huntington Disease Society of America, Vaccinex, AbbVie, Auspex Pharmaceuticals.
5:30 PM	128	Patient and Caregiver Experiences With the Diagnosis of Neurogenic Orthostatic Hypotension	L. Arthur Hewitt Disclosure: Dr. Hewitt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Lundbeck.
5:30 PM	129	Persistence of Droxidopa Treatment in Patients With Neurogenic Orthostatic Hypotension	Jan Basile Disclosure: Dr. Basile has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, Arbor Pharmaceuticals, Janssen Pharmaceuticals and Lundbeck.
5:30 PM	130	Management and Treatment of Neurogenic Orthostatic Hypotension: Results From a Survey of Patients and Caregivers	L. Arthur Hewitt Disclosure: Dr. Hewitt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Lundbeck.
5:30 PM	131	Short-Term Outcome in Children and Adolescents with Orthostatic Intolerance and Postural Tachycardia Syndrome	Imad Jarjour, MD, FAAN Disclosure: Dr. Jarjour has nothing to disclose.
5:30 PM	132	Joint Hypermobility is Related to Pathological Finding on Tilt Table Testing	Ivan Adamec Disclosure: Dr. Adamec has nothing to disclose.
5:30 PM	133	Running-Induced Vertigo in an Adolescent: A Treatable Orthostatic Vestibular Migraine Variant	Imad Jarjour, MD, FAAN Disclosure: Dr. Jarjour has nothing to disclose.
5:30 PM	134	Elevated Paraneoplastic Markers: An Uncommon Finding in Orthostatic Intolerance and Postural Orthostatic Tachycardia	Charlene Hoffman-Snyder Disclosure: Dr. Hoffman-Snyder has nothing to disclose.
5:30 PM	135	Postural Orthostatic Tachycardia: The Stanford experience	Safwan Jaradeh, MD, FAAN Disclosure: Dr. Jaradeh has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
5:30 PM	136	Isolated Sixth Cranial Nerve Palsy in Pregnancy	Noelia García Lax Disclosure: Dr. García Lax has nothing to disclose.
5:30 PM	137	A case of optic neuropathy due to cat scratch disease (CSD) and syphilis co-infection with characteristic MRI findings	MingYang Meah Gao, MD Disclosure: Dr. Gao has nothing to disclose.
5:30 PM	138	Wernicke's Encephalopathy After Hyperemesis Gravidarum	Pria Anand, MD Disclosure: Dr. Anand has nothing to disclose.
5:30 PM	139	A Case of Severe Wernicke Encephalopathy with Bilateral Sensorineural Hearing Loss	Michael Hansen Disclosure: Dr. Hansen has nothing to disclose.
5:30 PM	140	Objective Evidence of Hyper-rapid Olfactory Adaptation in Cranial Nerve I Dysfunction	Khurram Janjua Disclosure: Dr. Janjua has nothing to disclose.
5:30 PM	141	Hypereosinophilia and Neuro-ophthalmological manifestations in Lymphoma	Ehtesham Khalid, MBBS Disclosure: Dr. Khalid has nothing to disclose.
5:30 PM	142	Intraorbital Perineural Cyst of the Oculomotor Nerve	Laszlo Mechtler, MD, FAAN, FASN Disclosure: Dr. Mechtler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva, Promius, Allergan, Avanir, Amgen. Dr. Mechtler has received research support from DENT Family Foundation.
5:30 PM	143	Horner's Syndrome as the Presenting Symptom in Giant Cell Arteritis	Stephanie Figueira Disclosure: Dr. Figueira has nothing to disclose.
5:30 PM	144	Diplopia as the Presenting Symptom of Systemic T Cell Prolymphocytic Leukemia with Infiltration of the Superior Rectus Muscle.	Humaira Khan, MD Disclosure: Dr. Khan has nothing to disclose.
5:30 PM	145	Unilateral proptosis, scleral injection and superior gaze diplopia secondary to spontaneous ophthalmic artery to superior ophthalmic vein fistula - Case report and review of literature	Subin Mathew, MD Disclosure: Dr. Mathew has nothing to disclose.
5:30 PM	146	Development of Optic Neuritis after Vaccination, A CDC/FDA Vaccine Adverse Event Reporting System (VAERS) Study, 1990-2017.	Janaki Patel Disclosure: Dr. Patel has nothing to disclose.
5:30 PM	147	Chronic Relapsing Inflammatory Optic Neuropathy	Chaitanya Amrutkar, MD Disclosure: Dr. Amrutkar has nothing to disclose.
5:30 PM	148	Intravenous immunoglobulin treatment in the management of corticosteroid unresponsive optic neuritis: A retrospective case series of 15 cases	Yu Zhao Disclosure: Dr. Zhao has nothing to disclose.
5:30 PM	149	Clinical Features and Outcomes of Pediatric Monophasic and Recurrent Idiopathic Optic Neuritis	Soren Jonzzon Disclosure: Dr. Jonzzon has nothing to disclose.
5:30 PM	150	Audiological Profile of Multiple Sclerosis Patients in Jordan: A Case-Control Study.	Mohammad Alkhoujah Disclosure: Dr. Alkhoujah has nothing to disclose.
5:30 PM	152	Venous Sinus Stenting Improves Visual Fields and Cerebrospinal Fluid Opening Pressures in Patients with Idiopathic Intracranial Hypertension	Evan R Schloss, MD Disclosure: Dr. Schloss has nothing to disclose.
5:30 PM	153	Long-term Symptom Reduction of MdDS Rocking Vertigo with Theta Burst rTMS	Benjamin Chipper Doudican Disclosure: Dr. Doudican has nothing to disclose.
5:30 PM	154	'Sandbagging' a Vision Test for Concussion-based Sideline Assessment: An Eye Movement Investigation Objectively Reveals the 'Gamers' Strategies	Janet Rucker, MD Disclosure: Dr. Rucker has nothing to disclose.
5:30 PM	155	Field testing the ICHD 3 beta diagnostic criteria of vestibular migraine	Mark Obermann, MD Disclosure: Dr. Obermann has nothing to disclose.
5:30 PM	156	Psychological Measures of Individuals with Mal de Debarquement Syndrome	Diamond Gleghorn Disclosure: Dr. Urbano has nothing to disclose.
5:30 PM	157	Vestibular Perceptual Threshold and Motion Sensitivity in Vestibular Migraine and Persistent Postural-Perceptual Dizziness	Sebastian Wurthmann Disclosure: Dr. Wurthmann has nothing to disclose.
5:30 PM	158	Erlotinib-Induced Dandy's Syndrome: Case Report	Kristen Steenerson, MD Disclosure: Dr. Steenerson has nothing to disclose.
5:30 PM	159	Short-Term Memory Loss in Vestibular Patients can Arise Independently of Psychiatric Impairment, Fatigue and Sleeplessness	S.S. Surenthiran, MBBS Disclosure: Dr. Surenthiran has nothing to disclose.
5:30 PM	160	Optimal Inter-Eye Difference Thresholds in Retinal Nerve Fiber Layer and Ganglion Cell Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis: An International Collaborative Study	Rachel Nolan Disclosure: Dr. Nolan has nothing to disclose.
5:30 PM	161	Retinal Ganglion Cell Layer and Disease Activity in Clinically Isolated Syndrome	Hanna Zimmermann Disclosure: Dr. Zimmermann has nothing to disclose.
5:30 PM	162	Agonist of Growth Hormone Releasing Hormone (GHRH) Protects Retinal Ganglion Cells in a Model of Traumatic Optic Neuropathy	Christian Kim Disclosure: Dr. Kim has nothing to disclose.
5:30 PM	163	Evaluation of neuroprotective properties of dimethylfumarate by optical coherence tomography in non-inflammatory models of retinal neurodegeneration	Michael Dietrich Disclosure: Dr. Dietrich has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis.
5:30 PM	164	Mkk4 and Mkk7 are Important for Both Retinal Development and Axonal Injury-Induced Retinal Ganglion Cell Death	Stephanie Syc Disclosure: Dr. Syc has nothing to disclose.
5:30 PM	165	Correlation of Visual Field Loss with MRI Findings in Patients with Pituitary Tumours	Christian Lueck, MD, FAAN Disclosure: Dr. Lueck has received research support from Perpetual.
5:30 PM	166	Impact of cataract surgery on cognitive functions in elderly patients presenting to a tertiary care center in Islamabad.	Faleha Zafar Disclosure: Dr. Zafar has nothing to disclose.
5:30 PM	167	Saccadic Intrusions Are Rare In Multiple Sclerosis	Lisa DePledge Disclosure: Dr. DePledge has nothing to disclose.
5:30 PM	168	Correlative Enhancement: Evaluation of a new postprocessing algorithm for diagnosis of optic neuritis.	Leanne Stunkel, MD Disclosure: Dr. Stunkel has nothing to disclose.
5:30 PM	169	The New MULES: A Sideline-Friendly Test of Rapid Picture Naming for Concussion	Omar Akhand Disclosure: Dr. Akhand has nothing to disclose.
5:30 PM	170	NA	NA NA Disclosure:
5:30 PM	171	NA	NA NA Disclosure:
5:30 PM	172	NA	NA NA Disclosure:
Behavioral and Cognitive Neurology: Genes, Environment, and Interventions
Start Time	Pub.	Title	Presenter
5:30 PM	173	Homozygosity for the A431E mutation in PSEN1 presenting with a relatively aggressive phenotype	John Parker, MD Disclosure: Dr. Parker has nothing to disclose.
5:30 PM	174	Huntington's disease across four generations in a mexican family: Westphal variant with female predominance	Jazmin Sotelo-Hernandez Disclosure: Dr. Sotelo-Hernandez has nothing to disclose.
5:30 PM	175	Fahr's disease due to a novel SLC20A2 gene mutation in a Canadian patient: Early Neurocognitive, Structural and Metabolic changes	Leila Sellami, MD Disclosure: Dr. Sellami has nothing to disclose.
5:30 PM	176	Two Distinct Clinical Phenotypes in a Family with ALSP Caused by a Novel CSF-1R Mutation.	Ryan Taylor, MD Disclosure: Dr. Taylor has nothing to disclose.
5:30 PM	177	A Case of AARS2 Leucoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL)	Michael Doyle, MRCPI Disclosure: Dr. Doyle has nothing to disclose.
5:30 PM	178	Correlation Between Exercise and Motor Skills with Elderly Patients Cognition	Cassio Henrique Taques Martins Disclosure: Dr. Martins has nothing to disclose.
5:30 PM	179	Dietary Approaches to Stop Hypertension (DASH) Diet Associated with Lower Rates of Depression	Laurel Cherian, MD Disclosure: Dr. Cherian has nothing to disclose.
5:30 PM	180	An Exploratory Analysis of Lifetime Surgical History and Cognition	James Bateman, MD Disclosure: Dr. Bateman has nothing to disclose.
5:30 PM	181	Neurostimulation for Functional Weakness: A Longitudinal Evaluation of Cortical Neurophysiology	Matthew J Burke, MD Disclosure: Dr. Burke has nothing to disclose.
5:30 PM	182	'Just Google It' – The Effect of Media Events on Patterns of Public Interest in the 'Vaccines Cause Autism' Fallacy from 2004-2017	Shehryar Sheikh BA Disclosure: Dr. Sheikh has received research support from Eisai Inc..
Genetic and Basic Science Studies in Neurodegenerative Diseases
Start Time	Pub.	Title	Presenter
5:30 PM	183	Characterization of Regulatory T Lymphocytes in the progression of Alzheimer's Disease	Alirexa Faridar, MD Disclosure: Dr. Faridar has nothing to disclose.
5:30 PM	184	Age-Dependent White Matter Inflammation and Cognitive Impairment in the TgAPP21 Rat Model of Alzheimer Disease	Alexander Levit Disclosure: Dr. Levit has nothing to disclose.
5:30 PM	185	Case Control Study of RNA Editing in Blood Reveals Decreased Global Levels of A-to-I Editing in Alzheimer's Disease	Olivia Gardner Disclosure: Dr. Gardner has nothing to disclose.
5:30 PM	186	Genetic Basis of Motoric Cognitive Risk Syndrome in Health and Retirement Study	Sanish Sathyan Disclosure: Dr. Sathyan has nothing to disclose.
5:30 PM	187	Familial Adult-onset Neuronal Intranuclear Inclusion Disease	Monique Montenegro Disclosure: Dr. Montenegro has nothing to disclose.
5:30 PM	188	Amyloid-beta Induction of PIAS1 Ser-503 Phosphorylation and Elk-1 SUMOylation Mediate Endogenous Neuroprotection against Amyloid-beta Toxicity	Shau-Yu Liu Disclosure: Dr. Liu has nothing to disclose.
5:30 PM	189	Mutational Analysis of AARS2 in Japanese Patients with Adult-Onset Leukoencephalopathy Lacking CSF1R Mutation	Naomi Mezaki Disclosure: Dr. Mezaki has nothing to disclose.
5:30 PM	190	Identification and Functional Assay of Novel CSF1R Mutations in Patients with Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia	Takeshi MIURA Disclosure: Dr. Miura has nothing to disclose.
5:30 PM	191	Tau-related dysfunction of BRCA1 lead to reduced neuronal plasticity in Alzheimer's disease	Tatsuo Mano, MD, PhD Disclosure: Dr. Mano has nothing to disclose.
5:30 PM	192	Measuring the Contributions of Heritable and Non-Heritable Risk Factors to Alzheimer Disease Age-at-Symptomatic-Onset in Adult Children of Affected Parents	Gregory Day, MD, MSc Disclosure: Dr. Day has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with DynaMed (EBSCO Health).Dr. Day holds stock and/or stock options in ANI Pharmaceuticals.
5:30 PM	193	Clinical and neuropsychological features of a family with a novel PSEN-1 variant (I416T)	Laura Ramírez-Aguilar Disclosure: Dr. Ramírez-Aguilar has nothing to disclose.
5:30 PM	194	Genome-wide Association Study Based on A/T/N System Identifies New Susceptibility Loci for Alzheimer's Disease	Chenchen Tan Disclosure: Dr. Tan has nothing to disclose.
5:30 PM	195	African Haplotypic Background Mitigates the Effect of APOE e4 Risk Allele in Alzheimer Disease	Farid Rajabli Disclosure: Dr. Rajabli has nothing to disclose.
5:30 PM	196	TREM2 P.Arg47His Is Not Associated With Late-Onset Alzheimer's Disease In A Tunisian Population	Mouna Ben Djebara Disclosure: Dr. Ben Djebara has nothing to disclose.
5:30 PM	197	In vitro, In vivo and cerebrospinal fluid studies implicate decreased ABCA-1 activity with APOE4	Varun Rawat Disclosure: Dr. Rawat has nothing to disclose.
5:30 PM	198	Case Report: SPG4-related cognitive decline in a patient with deletion of exons 5-17	Elizabeth Coffee Disclosure: Dr. Coffee has nothing to disclose.
5:30 PM	199	NA	NA NA Disclosure:
5:30 PM	200	NA	NA NA Disclosure:
Stroke Epidemiology, Risk Factors, and Outcomes
Start Time	Pub.	Title	Presenter
5:30 PM	201	Characterizing Stroke in Transgender Adults - a San Francisco General Hospital Study	Sara LaHue, MD Disclosure: Dr. LaHue has nothing to disclose.
5:30 PM	202	The Role of Acute versus Ever Use of Cocaine in Ischemic Stroke of Young Adults	Sleiman El Jamal, MD Disclosure: Dr. El Jamal has nothing to disclose.
5:30 PM	203	Code 420: A case series of accidental marijuana ingestion masquerading as acute stroke	Katherine Werbaneth, MD Disclosure:
5:30 PM	204	Recreational Use Of Marijuana and Stroke: A Nationwide Outcome Study	Urvish Patel Disclosure: Dr. Patel has nothing to disclose.
5:30 PM	205	Impact of Cocaine Use on Acute Ischemic Stroke Patients: Insights from Nationwide Inpatient Sample in the United States	Zabeend Mahuwala, MD Disclosure: Dr. Mahuwala has nothing to disclose.
5:30 PM	206	History of Diabetes, Drug Abuse and Smoking Predicts Recurrence Rate of Ischemic Stroke in the Young	Muhammad Ahmed, MD Disclosure: Dr. Ahmed has nothing to disclose.
5:30 PM	207	Continued Nationwide decline in Stroke related In-Hospital Mortality in United States	Mohammad Rauf Afzal Disclosure: Dr. Afzal has nothing to disclose.
5:30 PM	208	Clinical Characteristics of Stroke Patients with Essential Thrombocytosis according to JAK2 mutation	Joung-Ho Rha, MD, PhD Disclosure: Dr. Rha has nothing to disclose.
5:30 PM	209	Trauma due to Acute Ischemic Stroke: A Case Series	Kevin Yeboah, MD Disclosure: Dr. Yeboah has nothing to disclose.
5:30 PM	210	Only hepatic fibrosis, not steatosis, assessed on transient elastography is an independent predictor of long-term mortality in patients with ischemic stroke.	Minyoul Baik, MD Disclosure: Dr. Baik has nothing to disclose.
5:30 PM	211	Level of Consciousness at Discharge and Associations with Outcome After Ischemic Stroke	Michael Reznik, MD Disclosure: Dr. Reznik has nothing to disclose.
5:30 PM	212	Aphasia at Presentation Predicts Poor Functional Outcome After Acute Ischemic Stroke	Kathleen L. Donahue Disclosure: Dr. Donahue has nothing to disclose.
5:30 PM	213	Cancer and Stroke - Presentations and Problems	David Collas, MD Disclosure: Dr. Collas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer and Pfizer.
5:30 PM	214	Stroke in Teens	Chandramouleeswaran Venkatraman Disclosure: Dr. Venkatraman has nothing to disclose.
5:30 PM	215	Development and Validation of Graphical Displays for Reporting Acute Stroke Trials that Use a Patient-Centered Disability Outcome Primary Endpoint	Ivie Tokunboh Disclosure: Dr. Tokunboh has nothing to disclose.
5:30 PM	216	Classical Crossed Medullary Syndromes in Patients with Lateral Medullary Infarction	Guillermo Delgado-García Disclosure: Dr. Delgado-Garcia has received personal compensation in an editorial capacity for Neurology, Resident and Fellow section. Dr. Delgado-Garcia has received research support from Fundacion Carlos Slim.
5:30 PM	217	Etiologies, risk factors and functional outcomes of young stroke in a Taiwanese cohort	Chun-Yu Chen Disclosure: Dr. Chen has nothing to disclose.
5:30 PM	218	Prevalence of HIV Infection Among Stroke Patients and its Association with Mortality in Southwestern Uganda	Amir Abdallah Disclosure: Dr. Abdallah has nothing to disclose.
5:30 PM	219	Incidence of Ischemic and Hemorrhagic Stroke Amongst Asians in the United States	Antonio Moya, MD Disclosure: Dr. Moya has nothing to disclose.
5:30 PM	220	Leukoaraiosis & Metabolic Syndrome In Middle Age Egyption Ischemic Stroke Patients	Wael Amer, MD Disclosure: Dr. Amer has nothing to disclose.
5:30 PM	221	Impact of Reactive Hyperglycemia on Stroke Severity and Outcome in Lagos, Nigeria	Osigwe Agabi, MD Disclosure: Dr. Agabi has nothing to disclose.
5:30 PM	222	Predictors of Stroke Recurrence at Lagos University Teaching Hospital,Nigeria.	Nosakhare Osemwegie Disclosure: Dr. Nosakhare has nothing to disclose.
5:30 PM	223	Clinical characteristics of borderzone infarction in Egyptian population	Nevine EL Nahas Disclosure: Dr. EL Nahas has nothing to disclose.
Stroke Biomarkers and Animal Models
Start Time	Pub.	Title	Presenter
5:30 PM	224	Neurovascular Protective Effects of Remote Ischemic Preconditioning in Acute Ischemic Stroke Model	Farris Taha Disclosure: Dr. Taha has nothing to disclose.
5:30 PM	225	Functional Remapping of the Mouse Somatosensory Cortex After Ischemic Stroke	William Zeiger, MD, PhD Disclosure: Dr. Zeiger has nothing to disclose.
5:30 PM	226	Multimodal Imaging of White Matter Inflammation in a Rat Model of Striatal Ischemic Stroke	Alexander Levit Disclosure: Dr. Levit has nothing to disclose.
5:30 PM	227	Blockade of Soluble Epoxide Hydrolase Attenuates Post-Ischemic Neuronal Hyperexcitation and Confers Resilience Against Stroke with TrkB Activation	Li-Hsin Chang Disclosure: Dr. Chang has nothing to disclose.
5:30 PM	228	Characterizing the Neuroinflammatory Response of Focal Ischemic Stroke in the Rat Insular Cortex	Victoria Thorburn Disclosure: Dr. Thorburn has nothing to disclose.
5:30 PM	229	Association of plasma D-dimer and B-type natriuretic peptide levels with stroke mechanism, severity, and outcome	Hyun-Wook Nah Disclosure: Dr. Nah has nothing to disclose.
5:30 PM	230	Role Of Blood Biomarkers In Differentiating Ischemic Stroke and Intracerebral Hemorrhage	Rohit Bhatia, MBBS,MD,DM Disclosure: Dr. Bhatia has nothing to disclose.
5:30 PM	231	Circulating inflammatory biomarkers are related to cerebrovascular disease in a non-demented elderly population	Yian Gu, PhD,DrPH Disclosure: Dr. Schupf has nothing to disclose.
5:30 PM	232	Diapedetic Potential of Monocytes in Complexes with Platelets Correlates with Clinical Outcome after Stroke	Maria Lukasik Disclosure: Dr. Lukasik has nothing to disclose.
5:30 PM	233	Multiple Biomarkers for the Prediction of Stroke Outcomes: Findings from a Cohort of 792 Patients with Ischemic Stroke in a University Teaching Hospital	Zuolu Liu Disclosure: Dr. Liu has nothing to disclose.
5:30 PM	234	Role Of Blood Biomarkers In Predicting Outcomes After Acute Stroke	Divya M Radhakrishnan Disclosure: Dr. MR has nothing to disclose.
5:30 PM	235	Marked Leukocytosis on Presentation with Acute Ischemic Stroke -- What Does it Mean?	Matthew Broderick, MD Disclosure: Dr. Broderick has nothing to disclose.
5:30 PM	236	Admission white blood cell count is associated with stroke severity and outcome independent of acute infarct size	Anne-Katrin Giese Disclosure: Dr. Giese has nothing to disclose.
5:30 PM	237	Can S100b, IL 6 And BNP Predict Functional Neurological Outcome In Intracerebral Hemorrhage?	Mohammed El-Sherif, MD Disclosure: Dr. El-Sherif has nothing to disclose.
5:30 PM	238	Role of Copeptin as a Biomarker for Predicting Outcome after Spontaneous Intracerebral Hemorrhage: A Prospective Cohort Study	Shubham Misra Disclosure: Dr. Misra has nothing to disclose.
5:30 PM	239	Role of Blood Based Biomarkers for Predicting Outcome after Spontaneous Intracerebral Hemorrhage: Findings from a Multi-Centric Prospective Cohort Study	Kameshwar Prasad, MD Disclosure: Dr. Prasad has nothing to disclose.
5:30 PM	240	A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for Ischemic Stroke	I-Chen Yu Disclosure: Dr. Yu has nothing to disclose.
Cerebrovascular Genetics
Start Time	Pub.	Title	Presenter
5:30 PM	241	Molecular Genetic Features Of Polymorphism Of The Gene Col4a1 Rs605143 G / A In The Development Of Pathological Deformations Of Cerebral Vessels In Patients With Migraine	Gulnora Rahmatullaeva Disclosure: Dr. Rahmatullaeva has nothing to disclose.
5:30 PM	242	The Cerebral Straight and Narrow: A Case Illustration of Moyamoya Syndrome in the Setting of the ACTA-2 Gene Mutation	Malcolm McDonald Disclosure: Dr. McDonald has nothing to disclose.
5:30 PM	243	Rare Presentation of Malignant Myxomatous Aneurysms with PRKAR1A gene mutation	Usman Shehzad, MD Disclosure: Dr. Shehzad has nothing to disclose.
5:30 PM	244	Molecular - Genetic Features Of The Gene Of Vasculoendothelial Growth Factor (C634G VEGFA) In The Deformations Of Cerebral Vessels	Gulnora Rahmatullaeva Disclosure: Dr. Rahmatullaeva has nothing to disclose.
5:30 PM	245	PAI-1 polymorphism and stroke in pregnancy	Mary Hollist, DO, MD Disclosure: Dr. Hollist has nothing to disclose.
5:30 PM	246	Ring-enhancing lesions, stroke and vascular retinopathy associated with a novel TREX1 mutation	Marcus Cimino, MD Disclosure: Dr. Cimino has nothing to disclose.
5:30 PM	247	Systemic Response to Rupture of Intracranial Aneurysms Analyzed with Whole-transcriptome Sequencing	Joanna Pera, MD Disclosure: Dr. Pera has nothing to disclose.
5:30 PM	248	Association of Transforming growth Factor-?1 gene C509T, G800A and T869C Polymorphisms with Intracerebral Hemorrhage in North Indian Population: A Case-Control Study	Shubham Misra Disclosure: Dr. Misra has nothing to disclose.
5:30 PM	249	Role Of Pharmacogenetics and Pharmacodynamics On The Antiplatelet Effect Of Clopidogrel In North Indian Ischemic Stroke Patients	Dheeraj Khurana, MD Disclosure: Dr. Khurana has nothing to disclose.
5:30 PM	250	Association between Tumor necrosis factor-alpha (-308G/A, +488G/A, -857C/T and -1031 T/C) gene polymorphisms and risk of ischemic stroke in north Indian population: A case-control study	Pumanshi Talwar Disclosure: Dr. Talwar has nothing to disclose.
Pre-Hospital, Telestroke and ED-Based Stroke Care II
Start Time	Pub.	Title	Presenter
5:30 PM	251	Safety and Feasibility of Telestroke in the Prehospital Emergency Medical Services Setting - The REACHOUT Project	Muhammad Adeel Saleemi Disclosure: Dr. Saleemi has nothing to disclose.
5:30 PM	252	Pre-arrival RACE Score-Based Hospital Bypass Protocol Improves Treatment Time Efficiencies	Shazli Khan Disclosure: Dr. Khan has nothing to disclose.
5:30 PM	253	Correlation between evaluation and documentation of neurologic deficit by EMS and ED of patients with acute ischemic stroke	Haitham Hussein, MD Disclosure: Dr. Hussein has nothing to disclose.
5:30 PM	254	A Prospective Validation of Stroke Network Of Wisconsin (SNOW) Scale	Kessarin Panichpisal Disclosure: Dr. Panichpisal has nothing to disclose.
5:30 PM	255	Safety of intravenous thrombolysis in telestroke and impact of an acute stroke training curriculum	Tarun Girotra, MD Disclosure: Dr. Girotra has nothing to disclose.
5:30 PM	256	NA	NA NA Disclosure:
5:30 PM	257	NA	NA NA Disclosure:
5:30 PM	258	NA	NA NA Disclosure:
Clinical Epilepsy II
Start Time	Pub.	Title	Presenter
5:30 PM	259	Baroreflex Sensitivity in Patients with Intractable Generalized Tonic Clonic Seizures versus Partial Seizures	Behnaz Esmaeili, MD Disclosure: Dr. Esmaeili has nothing to disclose.
5:30 PM	260	Evaluation of Dual Pathology Among Drug Resistant Epileptic Patients With Hippocampal Sclerosis	Peyman Gookizadeh Disclosure: Dr. Gookizadeh has nothing to disclose.
5:30 PM	261	A New Database Platform for Clinical and Genetic Investigation of Epilepsies and the New ILAE Classification	David Discua Disclosure: Dr. Discua has nothing to disclose.
5:30 PM	262	Initial Presentations and Surgical Outcomes of Pediatric Patients with Neurovascular Lesions	Janani Kassiri, MD, PhD Disclosure: Dr. Kassiri has nothing to disclose.
5:30 PM	263	Comparing the Clinical Profile and Seizure Control between Focal and Generalized Seizures in Adult Nigerian Patients with Epilepsy.	Chindo Mallum, MD Disclosure: Dr. Mallum has nothing to disclose.
5:30 PM	264	A Fatal Case of Mistaken Identity: Brugada Syndrome Masquerading as Seizure Disorder	Claribel Wee, MD Disclosure: Dr. Wee has nothing to disclose.
5:30 PM	265	Impact of Seizures in Temporal Lobe Epilepsy on Cognitive Functions and Imaging Features	Gyujoon Hwang Disclosure: Dr. Hwang has nothing to disclose.
5:30 PM	266	Clinical Significance of Bilateral Failures on Wada Memory Testing	Iffat Ara Suchita, MD Disclosure: Dr. Suchita has nothing to disclose.
5:30 PM	267	Seizure-induced Behavioral and Autonomic Arousal Localizes to the Anterior Cingulate Gyrus: Network Dynamics and Underlying Mechanism	Harshad Ladha, MD Disclosure: Dr. Ladha has nothing to disclose.
5:30 PM	268	Does A Drug Refractory Epilepsy (DRE) diagnosis impact time to seizures in the Epilepsy Monitoring Unit (EMU)	Brian Toh Disclosure: Dr. Toh has nothing to disclose.
5:30 PM	269	The Role Of Immunoreactivity Of Neurotropic Autoantibodies And Neuromediators In The Pathogenesis Of Symptomatic And Idiopathic Epilepsy	Marufjon Salokhiddinov Disclosure: Dr. Salokhiddinov has nothing to disclose.
5:30 PM	270	Epilepsy as a Dynamic Disease: Modeling Seizure Burden Based On Transitions Between Seizure Risk States	Sharon Chiang Disclosure: Dr. Chiang has nothing to disclose.
5:30 PM	271	Effect of Anesthesia on Electrocorticography for localization of Epileptic Focus: Literature Review and Future Directions	Ayse Bayram Disclosure: Dr. Bayram has nothing to disclose.
5:30 PM	272	Can We Predict the prognosis in patients with Acute Symptomatic Seizure? A Prognostic model: A Retrospective study from a developing nation	GOPAL KRISHNA DASH Disclosure: Dr. Dash has nothing to disclose.
Epilepsy: Basic Science and Genetics
Start Time	Pub.	Title	Presenter
5:30 PM	273	Characterization of a Novel Knock-in Mouse Model of KCNT1 Epileptic Encephalopathy	Lisseth Burbano Disclosure: Dr. Burbano has nothing to disclose.
5:30 PM	274	NLRP1 Inflammasome is Activated in Patients with Medial Temporal Lobe Epilepsy and Contributes to Neuronal Pyroptosis in Amygdala Kindling- induced Rat Model	Chenchen Tan Disclosure: Dr. Tan has nothing to disclose.
5:30 PM	275	Autophagy in Juvenile Myoclonic Epilepsy (JME)	Miyabi Tanaka Disclosure: Dr. Tanaka has nothing to disclose.
5:30 PM	276	NADPH oxidase inhibitor attenuated increased seizure susceptibility after systemic inflammation	Wan-Yu Huang Disclosure: Dr. Huang has nothing to disclose.
5:30 PM	277	A role of GPR55 in the antiepileptic properties of cannabidiol (CBD)	Benjamin J. Whalley Disclosure: Dr. Whalley is employed by GW Pharmaceuticals. Dr. Whalley holds stock and/or stock options in GW Pharmaceuticals, which sponsored research in which Dr. Whalley was involved as an investigator.
5:30 PM	278	Variation in Cortical Impact Augments Epileptogenesis in Rat Model of Traumatic Brain Injury.	SHAMMY CHANDEL Disclosure: Dr. Chandel has nothing to disclose.
5:30 PM	279	Protective effects of protocatechuic acid against seizure-induced neuronal death in the pilocarpine-induced status epilepticus rat model	Dong Jin Shin, MD Disclosure: Dr. Shin has nothing to disclose.
5:30 PM	280	Association Between Occurrence of Hippocampal Spindles and Hippocampal Interictal Spiking.	Kseniia K. Kriukova Disclosure: Dr. Kriukova has nothing to disclose.
5:30 PM	281	Majority of Epilepsy Mutations are in Genes with Therapeutic Associations	Elaine Weltmer Disclosure: Dr. Weltmer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ambry Genetics.
5:30 PM	282	Genotype and Phenotype Correlation in Patients with Comorbid Epilepsy and Intellectual Disability	Mohamed Taha, MD Disclosure: Dr. Taha has nothing to disclose.
5:30 PM	283	Screening of PI3K-AKT-mTOR pathway genes in focal cortical dysplasias in a clinical setting	Andrea Accogli Disclosure: Dr. Accogli has nothing to disclose.
5:30 PM	286	Prevalence and Impact of Consanguinity in Patients with Mesial Temporal Sclerosis in Saudi Population	Khalid Alqadi, MD Disclosure: Dr. Alqadi has nothing to disclose.
5:30 PM	287	Refractory Status Epilepticus and Chronic Kidney Disease in a Large Pedigree Due to a Variant in the Mitochondrial Encoded tRNA Phenylalanine (MT-TF) Gene	James H. Ellis, BS Disclosure: Dr. Ellis has nothing to disclose.
5:30 PM	288	Analysis of 234 Epilepsy Genes for Sequence and Copy Number Variants Using Next Generation Sequencing	Zhenyuan Wang Disclosure: Dr. Wang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Quest Diagnostics. Dr. Wang has received research support from Quest Diagnostics.
5:30 PM	289	Genetic Testing has taken out Guesswork: Cases of Familial and Non-familial Benign Infantile Epilepsy Associated with PRRT2 gene mutations.	Yoshimi Hisamoto, MD Disclosure: Dr. Hisamoto has nothing to disclose.
5:30 PM	290	NA	NA NA Disclosure:
5:30 PM	291	NA	NA NA Disclosure:
5:30 PM	292	NA	NA NA Disclosure:
5:30 PM	293	NA	NA NA Disclosure:
5:30 PM	294	NA	NA NA Disclosure:
Child Neurology and Developmental Neurology: Epilepsy
Start Time	Pub.	Title	Presenter
5:30 PM	295	EEG Patterns in Routine Polysomnography in Childhood and Risk of Epilepsy	Robert Stowe, MD Disclosure: Dr. Stowe has nothing to disclose.
5:30 PM	296	New Onset Refractory Status Epilepticus in Pediatric Population: A Single Tertiary Center Experience	Khalil Husari, MD Disclosure: Dr. Husari has nothing to disclose.
5:30 PM	297	Cognitive, Linguistic and Behavioral Characteristics of Children with Comorbid Autism Spectrum Disorder and Epilepsy	Louisa Kalsner, MD Disclosure: Dr. Kalsner has nothing to disclose.
5:30 PM	298	Evaluation of new onset seizures presenting to the Pediatric Emergency Department(ED). A quality improvement study based on the AAN, CNS and AES practice parameters (2010).	Nitish Chourasia, MD Disclosure: Dr. Chourasia has nothing to disclose.
5:30 PM	299	Cognitive Outcomes In Children With Infantile Spasms: Successful Treatment Response Is Beneficial Regardless Of Etiology	Nonita Mittal, MBBS Disclosure: Dr. Mittal has nothing to disclose.
5:30 PM	300	The clinical and electroencephalographic spectrum of ESES (Encephalopathy with status epilepticus in sleep) in Indian children	Priyanka Madaan Disclosure: Dr. Madaan has nothing to disclose.
5:30 PM	301	Long-Term Prognostic Patterns In Pediatric Epilepsy: A Review Of Literature.	Kushal Naik Disclosure: Dr. Naik has nothing to disclose.
5:30 PM	302	Rectal Administration of Vigabatrin Achieves Higher Plasma Concentration than Oral Administration.	Mohammad Hamed Disclosure: Dr. Hamed has nothing to disclose.
5:30 PM	303	Utilizing Quality Improvement Strategies to Increase Continuous EEG Monitoring in Critically Ill Pediatric Patients with Persistent Encephalopathy Following Status Epilepticus	Asri Yuliati Disclosure: Dr. Yuliati has nothing to disclose.
5:30 PM	304	Expanding the clinical spectrum of the rare epilepsy syndrome of Benign Infantile Focal Epilepsy with Midline Spikes (BIMSE)	Reema Butt Disclosure: Dr. Butt has nothing to disclose.
5:30 PM	305	Drug-Resistant Epilepsy and Neurodevelopmental Disabilities in Randomized Controlled Trials of Therapeutic Devices	Lydia Bernhardt Disclosure: Dr. Bernhardt has nothing to disclose.
Child Neurology and Developmental Neurology: Infectious, Inflammatory, and Autoimmune Disorders
Start Time	Pub.	Title	Presenter
5:30 PM	306	The Spectrum of Myelopathies in Children: Beyond Idiopathic Transverse Myelitis	Laura Munoz-Arcos, MD Disclosure: Dr. Munoz-Arcos has nothing to disclose.
5:30 PM	307	Cerebrospinal fluid (CSF) Neurofilament and CXCL-13 Levels in Children with Demyelinating Disease	Maria Galardi Disclosure: Dr. Galardi has nothing to disclose.
5:30 PM	308	Pediatric and Adult MS: A Longitudinal Multimodal MRI Study to Explore the Substrates of the Different Clinical Courses	Ermelinda De Meo Disclosure: Dr. De Meo has nothing to disclose.
5:30 PM	309	Chitinase 3-like 1 and Neurofilament Light Chain Predict Pediatric Demyelination	Magnus Spangsberg Boesen Disclosure: Dr. Spangsberg Boesen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva, Novartis, Roche.
5:30 PM	310	CT Scan Findings in Microcephaly Cases During 2015-2016 Zika Outbreak: A Cohort Study	Tabata De Alcantara Disclosure: Dr. De Alcantara has nothing to disclose.
5:30 PM	311	Use of Induction Immunotherapy Plus Rituximab for the Treatment of Pediatric Opsoclonus-Myoclonus Syndrome	Colin Wilbur, MD Disclosure: Dr. Wilbur has nothing to disclose.
5:30 PM	312	To determine the prevalence of neurologic syndromes, intellectual disability, abnormal behavior and sleep related problems in HIV infected children	Rajni Farmania Disclosure: Dr. Farmania has nothing to disclose.
5:30 PM	313	Autoimmune encephalitis in children: Clinical profile and outcome from a single tertiary care centre in India	Sheffali Gulati Disclosure: Dr. Gulati has nothing to disclose.
5:30 PM	314	Radiological Findings and Neurological Disorders in Microcephaly Cases Related to Zika Virus: A Cohort Study	Tabata De Alcantara Disclosure: Dr. De Alcantara has nothing to disclose.
5:30 PM	315	Gait variability is related to attention and information processing speed in adolescents with multiple sclerosis	Shay Menascu Disclosure: Dr. Menascu has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi-Genzyme and Merck/EMD Serono.
5:30 PM	316	A Case of Cognitive and Behavioral Decline leading to Onset of Pediatric Onset Multiple Sclerosis	Janet Elgallab, MD Disclosure: Dr. Elgallab has nothing to disclose.
5:30 PM	317	A Case Series of Acute Flaccid Myelitis in Pediatric Patients	Lydia Marcus, MD Disclosure: Dr. Marcus has nothing to disclose.
5:30 PM	318	Imaging of the Mechanisms of Thalamic Damage in Pediatric Multiple Sclerosis	Ermelinda De Meo Disclosure: Dr. De Meo has nothing to disclose.
5:30 PM	319	Miller Fisher Syndrome in a Case of Identical Twins	Tayyba Anwar, MD Disclosure: Dr. Anwar has nothing to disclose.
5:30 PM	320	Pediatric Acute Flaccid Myelitis: A Case Series	Alison Christy, MD, PhD Disclosure: Dr. Christy has nothing to disclose.
5:30 PM	321	Chiari malformations associated with transverse myelitis: are these myelopathies truly inflammatory?	Eliza Gordon-Lipkin, MD Disclosure: Dr. Gordon-Lipkin has nothing to disclose.
Child Neurology and Developmental Neurology: Neuromuscular Disease
Start Time	Pub.	Title	Presenter
5:30 PM	322	Ambulatory function and fatigue in nusinersen-treated children with spinal muscular atrophy.	Jacqueline Montes, PT, EdD, NCS Disclosure: Dr. Montes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Advisory boards for Astellas, Biogen, Cytokinetics, Roche, and Scholar Rock; consultant to Ionis Pharmaceuticals, Inc and Biogen. Dr. Montes has received research support from Research support from MDA and the NICHD / NIH.
5:30 PM	323	Safety profile of abobotulinumtoxinA (Dysport®) for lower limb spasticity: Pooled analysis of controlled clinical trials	Ann Tilton, MD, FAAN Disclosure: Dr. Tilton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen Pharma. Dr. Tilton has received research support from Ipsen Pharma.
5:30 PM	324	Safety and Efficacy of Nusinersen in Infants/Children with Spinal Muscular Atrophy (SMA): Part 1 of the Phase 2 EMBRACE Study	Perry B. Shieh, MD, PhD Disclosure: Dr. Shieh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion; AveXis, Inc.; Biogen; Grifols; PTC; Sarepta. Dr. Shieh has received research support from AveXis, Inc.; Audentes; Biogen; Bristol-Myers Squibb; Cytokinetics; Catalyst; Fibrogen; Ionis Pharmaceuticals, Inc.; Marathon; Pfizer; PTC; Sarepta; Santhera; Summit; Sanofi/Genzyme; Ultragenyx.
5:30 PM	325	Meta-Analysis of Deflazacort vs Prednisone/Prednisolone in Patients with Duchenne Muscular Dystrophy	Basil Darras, MD Disclosure: Dr. Darras has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, Biogen, Bristol-Myers Squibb, Cytokinetics, Marathon, PTC Therapeutics, Roche, Santhera, and Sarepta. Dr. Darras has received research support from the National Institutes of Health/National Institute of Neurological Disorders and Stroke, the Slaney Family Fund for SMA, Working on Walking Fund, the SMA Foundation, CureSMA, Ionis Pharmaceuticals, Inc., Biogen, AveXis, Cytokinetics, Fibrogen, PTC Therapeutics, Roche, Santhera, Sarepta, and Summit.
5:30 PM	326	Pediatric Myasthenia Gravis After Vaccination in the United States. A Report from the CDC/FDA Vaccine Adverse Event Reporting System. (1990-2017)	Rajanigandhi Hanumanthu, MD Disclosure: Dr. Hanumanthu has nothing to disclose.
5:30 PM	327	Evaluation of Childhood Weakness: Utilization of a Web-Based Educational Tool childmuscleweakness.org	Ann Martin Disclosure: Dr. Martin has nothing to disclose.
5:30 PM	328	Predicting Ambulatory Aid Needs with Disease Progression in Charcot-Marie-Tooth Disease	Sindhu Ramchandren, MD Disclosure: Dr. Ramchandren has nothing to disclose.
5:30 PM	329	Design of a Phase 3 Trial to Evaluate the Long-Term Efficacy and Safety of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy	Panayiota Trifillis Disclosure: Dr. Trifillis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics, Inc.
5:30 PM	330	Assessment of Practice Patterns and Knowledge of Pathophysiology for Spinal Muscular Atrophy Among Neurologists	John Maeglin Disclosure: Dr. Maeglin has nothing to disclose.
5:30 PM	331	Slope Analysis of 6-Minute Walk Dstance as an Alternative Method to Determine Treatment Effect in Trials in Duchenne Muscular dystrophy	Panayiota Trifillis Disclosure: Dr. Trifillis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics, Inc.
5:30 PM	332	Tolerability of Eteplirsen for Duchenne Muscular Dystrophy in the Youngest Reported Patient Treated With This Therapy	Sonam Bhalla, MD Disclosure: Dr. Bhalla has nothing to disclose.
5:30 PM	333	Cervical Puncture to Deliver Nusinersen in Patients with Spinal Muscular Atrophy and no Lumbar Access	Aravindhan Veerapandiyan, MD Disclosure: Dr. Veerapandiyan has nothing to disclose.
5:30 PM	334	A unique presentation of rapidly fluctuating symptoms in a child diagnosed with Congenital Myasthenic Syndrome due to RAPSN mutation.	Ashutosh Kumar, MD Disclosure: Dr. Kumar has received research support from Marathon, Sarepta Therapeutics.
5:30 PM	335	Focal Myositis of the Iliopsoas in a Young Girl with Recurrent Symptoms: A Case Report	Stephanie Manberg, DO Disclosure: Dr. Manberg has nothing to disclose.
5:30 PM	336	Unexpected Neuromuscular Diagnoses from Chromosomal Microarrays	Rebecca Luke, DO Disclosure: Dr. Luke has nothing to disclose.
5:30 PM	337	NA	NA NA Disclosure:
5:30 PM	338	NA	NA NA Disclosure:
Epilepsy/Clinical Neurophysiology (EEG) ePoster Session
Start Time	Pub.	Title	Presenter
5:30 PM	339	Seizure Risk From Intraoperative Motor Evoked Potential Stimulation	Viet Nguyen, MD Disclosure: Dr. Nguyen has nothing to disclose.
5:30 PM	340	Mesial Temporal Sclerosis (MTS) Undetected by MRI of the Brain	Miad Albalawi, MD Disclosure: Dr. Albalawi has nothing to disclose.
5:30 PM	341	Long Term Effects of Vagal Nerve Stimulation on Seizure Control and Quality of Life	Justin Abraham, MD Disclosure: Dr. Abraham has nothing to disclose.
5:30 PM	342	Unilateral deep brain stimulation masks undiagnosed epilepsy in a Parkinson's Disease patient: A Case Report	Alexis Taylor Disclosure: Dr. Taylor has nothing to disclose.
5:30 PM	343	EEG Cap Placement for Expedited Identification of Non-Convulsive Status Epilepticus	Jake McKay, MD Disclosure: Dr. McKay has nothing to disclose.
5:30 PM	344	Analyzing Phenotypes Using Artificial Intelligence Tools in Subgroups of Absence and Myoclonic Epilepsies	Reyna M. Durón Disclosure: Dr. Duron has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbott.
MS Modifiable Risk Factors
Start Time	Pub.	Title	Presenter
5:30 PM	345	Hypertension and heart disease are independently associated with development of brain atrophy in multiple sclerosis patients. A 5-year longitudinal study	Dejan Jakimovski Disclosure: Dr. Jakimovski has nothing to disclose.
5:30 PM	346	The Impact of Socioeconomic Status on Treatment Choice in Patients with Multiple Sclerosis.	Saul Reyes Disclosure: Dr. Reyes has received research support from SR has received an ECTRIMS clinical training fellowship in 2018.
5:30 PM	347	Vitamin D and physical activity in multiple sclerosis	Florian Deisenhammer, MD Disclosure: Dr. Deisenhammer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Celgene, Genzyme, Merck, Novartis, and Roche. Dr. Deisenhammer has received research support from by Biogen and Genzyme-Sanofi.
5:30 PM	348	Depression Severity Among Multiple Sclerosis Patients In Saudi Arabia-Cross Sectional Study	Adel Ali Alhazzani Disclosure: Dr. Alhazzani has nothing to disclose.
5:30 PM	349	Vitamin B12 and its impact on Multiple Sclerosis Type and Severity	Shymaa Buhlaiqah Disclosure: Dr. Hussain has nothing to disclose.
5:30 PM	350	Cesarean delivery and artificial lactation are associated with an earlier age of disease onset in multiple sclerosis	Vittorio Martinelli Disclosure: Dr. Martinelli has nothing to disclose.
5:30 PM	351	Distinct Effects of Obesity and Vitamin D on Risk of Multiple Sclerosis: A Mendelian Randomization Study	Adil Harroud, MD Disclosure: Dr. Harroud has nothing to disclose.
5:30 PM	352	Vitamin D Levels and Clinical and OCT measures in Progressive Multiple Sclerosis	Justin Abbatemarco, MD Disclosure: Dr. Abbatemarco has nothing to disclose.
5:30 PM	353	Longer Sleep Duration is Linked to Preserved Cortical Gray Matter Volume in Early MS	Michelle Fabian, MD Disclosure: Dr. Fabian has nothing to disclose.
5:30 PM	354	Risk Factors Associated with Multiple Sclerosis in Bogotá, Colombia.	Jaime Toro, MD, FAAN Disclosure: Dr. Toro has received personal compensation in an editorial capacity for New England Journal of Medicine Journal Watch Neurology and Multiple Sclerosis and Related Disorders.
5:30 PM	355	The Gut Microbiome in Relapsing Multiple Sclerosis Patients Compared to Controls.	Raffaella Umeton, MD Disclosure: Dr. Umeton has nothing to disclose.
5:30 PM	356	Fecal Microbial Transplantation in Multiple Sclerosis: trial design.	Ana Cristina Wing Disclosure: Dr. Dos Santos has nothing to disclose.
5:30 PM	357	Gut microbiota and metagenomic diversity in Clinical Isolated Syndrome	Simona Rolla Disclosure: Dr. Rolla has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi-Genzyme.
5:30 PM	358	A Paleolithic Diet-Based Intervention Decreases Multiple Sclerosis Fatigue via Lipid Profile Changes	Murali Ramanathan, PhD Disclosure: Dr. Ramanathan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with EMD Serono, Biogen Idec, Pfizer Inc, the National Multiple Sclerosis Society, the Department of Defense, Jog for the Jake Foundation, the National Institutes of Health and National Science Foundation. Dr. Ramanathan has received personal compensation in an editorial capacity for Editor from the American Association of Pharmaceutical Scientists. Dr. Ramanathan has received research support from EMD Serono, Biogen Idec, Pfizer Inc, the National Multiple Sclerosis Society, the Department of Defense, Jog for the Jake Foundation, the National Institutes of Health and National Science Foundation.
5:30 PM	359	Stress-induced Brain Activity, Brain Atrophy, and Clinical Disability in Multiple Sclerosis	Lil Meyer-Arndt Disclosure: Dr. Meyer-Arndt has nothing to disclose.
5:30 PM	360	Case Series of Four High School Football Players with Multiple Sclerosis	Cynthia Wang, MD Disclosure: Dr. Wang has nothing to disclose.
5:30 PM	361	Nutrition in the First Year Following the Diagnosis of Multiple Sclerosis	Yujie Wang, MD Disclosure: Dr. Wang has nothing to disclose.
MS Diagnosis, Mimickers, and Phenotypes
Start Time	Pub.	Title	Presenter
5:30 PM	362	Sarcoidosis Presenting as Intramedullary Spinal Cord Lesions	Prateek Thatikunta Disclosure: Dr. Thatikunta has nothing to disclose.
5:30 PM	363	When It's Not Multiple Sclerosis: Progressive White Matter Lesions with Inflammation	Julia Bucklan, DO Disclosure: Dr. Bucklan has nothing to disclose.
5:30 PM	364	Comorbidity in ultiple Sclerosis is associated with Diagnostic Delays and Increased Mortality	Anja Thormann Disclosure: Dr. Thormann has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adelphi Communications Ltd..
5:30 PM	365	Population-Based Prospective Cohort of RRMS Patients Who Declined or Delayed Disease-Modifying Therapy	Abdulaziz Al Sultan Disclosure: Dr. Al Sultan has nothing to disclose.
5:30 PM	366	Assessment of Relative Importance of Disease Modifying Treatment (DMT) Attributes in Multiple Sclerosis (MS) Patients	Tobias Sejbaek Disclosure: Dr. Sejbaek has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Merck, Novartis, Teva.
5:30 PM	367	Late Onset Fabry Disease: A Mimicker of CNS Demyelinating Disease	Subhendu Rath, MBBS Disclosure: Dr. Rath has nothing to disclose.
5:30 PM	368	The phenotype of Argentinean Multiple Sclerosis patients is similar to Multiple Sclerosis patients from other regions and has remained stable over the past decade.	Mariano Marrodan Disclosure: Dr. Marrodan has nothing to disclose.
5:30 PM	369	Impact of Gender on 30-day Readmission After Primary Admissions for Multiple Sclerosis: A Nationwide Readmission Database Analysis	Smit Patel Disclosure: Dr. Patel has nothing to disclose.
5:30 PM	370	Residual disability of acute severe multiple sclerosis relapses	Anat Achiron, MD, PhD, FAAN Disclosure: Dr. Achiron has nothing to disclose.
5:30 PM	371	Clinical and Immunologic Characterization of MRI-Defined Phenotypes in Multiple Sclerosis: a Longitudinal Study	Christopher Hemond, MD Disclosure: Dr. Hemond has nothing to disclose.
5:30 PM	372	Retinal Vasculopathy with Cerebral Leukoencephalopathy (RVCL): A Rare Familial Mimic of Tumefactive Multiple Sclerosis (MS)	Asaff Harel, MD Disclosure: Dr. Harel has nothing to disclose.
5:30 PM	373	An Extremely Aggressive case of Marburg's Disease	Jose Avila-Ornelas, MD Disclosure: Dr. Avila-Ornelas has nothing to disclose
5:30 PM	374	Spectrum of Peripheral Facial Involvement in Central Demyelinating Diseases	Elias Samaha, MD Disclosure: Dr. Samaha has nothing to disclose.
MS Epidemiology and Genetics
Start Time	Pub.	Title	Presenter
5:30 PM	375	Impact of age at relapse on recovery: An EDSS-recovery model for clinical trials	Burcu Zeydan, MD Disclosure: Dr. Zeydan has nothing to disclose.
5:30 PM	376	Predictors of Vocational Status Among Persons with Multiple Sclerosis	Sarah Morrow, MD, MSC,FRCPC Disclosure: Dr. Morrow has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, EMD Serono, Genzyme, Novartis, Roche. Dr. Morrow has received research support from Novartis, Roche.
5:30 PM	377	Relevance of Age and Cerebrospinal Fluid Measures in Multiple Sclerosis associated with seizures	Shitiz Sriwastava, MBBS Disclosure: Dr. Sriwastava has nothing to disclose.
5:30 PM	378	Bone Microarchitecture and Bone Mineral Density in Multiple Sclerosis	Anna Olsson Disclosure: Dr. Olsson has received research support from has received support for congress participation from Teva and Merck.
5:30 PM	379	Impact of multiple comorbidities on EDSS at presentation in patients with multiple sclerosis: A cross-sectional study.	Faisal Alsallom, MD Disclosure: Dr. Alsallom has nothing to disclose.
5:30 PM	380	Estimated prevalence of secondary progressive multiple sclerosis in the USA and Europe: results from a systematic literature search	Vivek Khurana Disclosure: Dr. Khurana has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Healthcare Private Limited.
5:30 PM	381	Erdheim-Chester Disease in the Brainstem Mimicking Tumefactive Demyelination.	Maria del Pilar Guillermo Prieto Eibl Disclosure: Dr. Prieto Eibl has nothing to disclose.
5:30 PM	382	Differential Expression of Alternative Splicing Variants in Individuals with Relapsing-Remitting Multiple Sclerosis	Michael Hecker, PhD Disclosure: Dr. Hecker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer HealthCare, Biogen, Novartis and Teva.
5:30 PM	383	Development of Multiple Sclerosis relapse flare after Vaccination, A CDC/FDA Vaccine Adverse Event Reporting System (VAERS) Study, [1987-2017].	Moamina Fakhera Eddin Disclosure: Dr. Fakhera Eddin has nothing to disclose.
5:30 PM	384	EMPLOYMENT SITUATION IN BRAZILIAN PATIENTS DIAGNOSED WITH MULTIPLE SCLEROSIS	Denis Bichuetti, MD Disclosure: Dr. Bichuetti has received personal compensation for speaking/consulting from Bayer Health Care, Biogen Idec, Merck Serono, Genzyme-Sanofi, TEVA and Roche, and had travel expenses to scientific meetings sponsored by Bayer Health Care, Merck Serono, TEVA and Roche.
5:30 PM	385	Impact of Age on 30-day Readmission After Primary Admission for Multiple Sclerosis: A Nationwide Readmission Databse Analysis	Smit Patel Disclosure: Dr. Patel has nothing to disclose.
5:30 PM	386	The Prevalence and Special Characteristic of Multiple Sclerosis that Begins in Older Adults	Estefanía García Molina Disclosure: Dr. Valero López has nothing to disclose.
5:30 PM	387	Does Co-morbidity with Familial Mediterranean Fever change the course of Multiple Sclerosis?	Aksel Siva, MD Disclosure: Dr. Siva has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Novartis, Teva, Genzyme, Bayer, Roche.
5:30 PM	388	Protective role of Multiple Sclerosis in Stroke; Analysis of a large national data base	Maryam Zulfiqar Disclosure: Dr. Zulfiqar has nothing to disclose.
5:30 PM	389	A Whole-Exome Sequencing Study In Multiple Sclerosis Multiplex Families	Elisabetta Mascia Disclosure: Dr. Mascia has nothing to disclose.
5:30 PM	390	The Saudi Arabian National Multiple Sclerosis Registry (NMSR): Initial Results Saudi MS Registry Study Group*	M. Al-Jumah, MD, MBBS Disclosure: Dr. Al-Jumah has nothing to disclose.
5:30 PM	391	Demyelination and Neurodegeneration along the Visual Pathway are more prominent in Secondary Progressive than Primary Progressive Multiple Sclerosis.	Simone Guerrieri Disclosure: Dr. Guerrieri has nothing to disclose.
5:30 PM	392	Regional thalamic volumes preferentially correlate with extra-thalamic white matter injury and clinical disability in multiple sclerosis subtypes	Kedar Mahajan, MD, PhD Disclosure: Dr. Mahajan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme.
5:30 PM	393	Predictors of Conversion to Secondary Progressive Multiple Sclerosis in Patients With Relapsing-Remitting Multiple Sclerosis	Davorka Tomic Disclosure: Dr. Tomic has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Novartis Pharma AG.
5:30 PM	394	Predicting Physical and Mental Disability in Patients with Multiple Sclerosis: a Longitudinal Analysis of Electronic Health Records.	Farren Briggs Disclosure: Dr. Briggs has nothing to disclose.
5:30 PM	395	New versus old: Implications of diagnostic criteria for Relapsing Remitting Multiple Sclerosis	Nuala McNicholas, MBBS Disclosure: Dr. McNicholas has nothing to disclose.
5:30 PM	396	Familial Multiple Sclerosis: An Epidemiological Study in Pontevedra, Spain.	Ana Rodriguez Regal Disclosure: Dr. Rodriguez Regal has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme, Biogen and TEVA.
5:30 PM	397	Increased Risk of Ischemic Stroke Associated with Untreated Multiple Sclerosis: A Nationwide Case-Control Population-Based Study.	Asad Ikram, MD, MBBS Disclosure: Dr. Ikram has nothing to disclose.
5:30 PM	398	The North American Registry for Care and Research in Multiple Sclerosis	Anne H. Cross, MD Disclosure: Dr. Cross has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Celgene, EMD Serono, Genzyme, Genentech, Novartis. Dr. Cross has received research support from Genentech.
5:30 PM	399	Long-term disability outcomes in relapsing-remitting multiple sclerosis: A 10-year follow-up study	Jelena Drulovic Disclosure: Dr. Drulovic has received personal compensation for serving on scientific advisory boards with Bayer Schering Pharma; Merck Serono, Teva, Genzyme, and Roche. Dr. Drulovic has received speaking honoraria from Merck Serono, Teva, Bayer Schering, Genzyme, Medis, and Roche. Dr. Drulovic has received research grant support from the Ministry of Education and Science and the Republic of Serbia (project no.175031).
5:30 PM	400	Patient Perspectives on Discontinuing Disease Modifying Therapies in the NARCOMS Registry	Marisa McGinley, DO Disclosure: Dr. McGinley has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme and Genentech. Dr. McGinley has received research support from Sylvia Lawry Physician Fellowship Grant through the National Multiple Sclerosis Society (#FP-1506-04742).
MS Animal Models
Start Time	Pub.	Title	Presenter
5:30 PM	401	Astrocyte Transciptomics in EAE Lead to Cholesterol Homeostasis as a New Treatment Target	Noriko Itoh Disclosure: Dr. Itoh has nothing to disclose.
5:30 PM	402	Longitudinal Diffusion Tensor Imaging in Theiler's Murine Encephalomyelitis Virus Driven Mouse Model of MS Reveals White Matter Change	Ely Cuberos Disclosure: Dr. Cuberos has nothing to disclose.
5:30 PM	403	Interaction of Normal and Antineuronal IgGs with Neurons in Rat Brain Slice Cultures: Comparison of IgG Uptake, Clearance, Intraneuronal Binding to Target Antigens, and Production of Neuronal Death	John Greenlee, MD, FAAN Disclosure: Dr. Greenlee has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Compensation as an expert witness for the law firm Wheeler, Trigg, and O’Donnell. Dr. Greenlee has received personal compensation in an editorial capacity for I received personal compensation for serving as author and associate editor for Medlink and for serving as an author for the Merck Manual, Professional and Home versions..
5:30 PM	404	Estrogen Receptor ? Ligand Acts on Two Pathways Within the CNS to Mediate Neuroprotection in the MS Model	Roy Kim Disclosure: Dr. Kim has nothing to disclose.
5:30 PM	405	Cellular Senescence Correlates with Demyelination, Brain Atrophy and Motor Impairment in a Model of Multiple Sclerosis	Maria Karamita Disclosure: Dr. Karamita has nothing to disclose.
5:30 PM	406	IL-11 antagonist suppresses Th17 cells-mediated neuroinflammation and demyelination in a mouse model of relapsing-remitting multiple sclerosis	Xin Zhang Disclosure: Dr. Zhang has nothing to disclose.
5:30 PM	407	IL-11-stimulated Encephalitogenic CD4+ Cells Induce Aggressive RREAE, Mediated via Th17, CD8+, CD19+ Cells and Neutrophils' Migration to CNS in Passive Transfer RREAE	Nazanin Kiapour Disclosure: Dr. Kiapour has nothing to disclose.
5:30 PM	408	Teriflunomide (Aubagio®) decreases microglial density in Theiler's Murine Encephalomyelitis Virus model of demyelination: Histological approach in combination with neuroimaging	Suyog Pol, PhD Disclosure: Dr. Pol has nothing to disclose.
5:30 PM	409	BDNF is necessary for neuronal activity-regulated oligodendrogenesis	Anna Geraghty Disclosure: Dr. Geraghty has nothing to disclose.
5:30 PM	410	Effect of Subcutaneous vs Intravenous Chronic Treatment with an Anti-CD20 Antibody on B-, T- and Myeloid Lymphocyte Subsets in Blood, Lymph Nodes and Spleen of C57BL/6 Mice	Anna Schubart Disclosure: Dr. Schubart is and employee of Novartis.
5:30 PM	411	Complete Resolution of Clinical Signs and Synergism of the Combination Ponesimod-dimethyl Fumarate in Rat Models of Multiple Sclerosis	Laetitia Pouzol Disclosure: Dr. Pouzol has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion Pharmaceuticals Ltd.
5:30 PM	412	Cerebrospinal Fluid Derived from Primary Progressive MS Delays Remyelination after Lysolecithin-induced Demyelination	Nathan Kung Disclosure: Dr. Kung has nothing to disclose.
5:30 PM	413	Dietary Conjugated Linoleic Acid Supplementation Modulates CNS Autoimmunity	Ann-Katrin Fleck Disclosure: Dr. Fleck has nothing to disclose.
5:30 PM	414	Passive transfer of human aquaporin-4 IgG autoantibodies causes complement-independent spinal cord immunopathologies in mice	Koon Chan, MD, MBBS Disclosure: Dr. Chan has nothing to disclose.
MS and CNS Inflammatory Disease: Quality of Life, Symptoms, and Symptomatic Therapy II
Start Time	Pub.	Title	Presenter
5:30 PM	415	Neurocognitive Correlates of Impaired Perceptual Decision-Making in MS and their Link to Quality of Life	Martin Weygandt, PhD Disclosure: Dr. Weygandt has nothing to disclose.
5:30 PM	416	Treatment satisfaction and illness perception in MS patients	Jarrett Leech Disclosure: Dr. Leech has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Onnit Labs, LLC. Dr. Leech has received compensation for serving on the Board of Directors of Onnit Labs, LLC.
5:30 PM	417	Pain Network and Neuropsychological Profile in Multiple Sclerosis and Migraine Patients	Claudio Gobbi, MD Disclosure: Dr. Gobbi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Biogen, Merck, Almirall, Roche, TEVA.
5:30 PM	418	Neuroanatomical Correlates of Latent Variables Speed and Memory in Early Multiple Sclerosis	Ilena George, MD Disclosure: Dr. George has nothing to disclose.
5:30 PM	419	Exploring Cannabis use by Patients with Multiple Sclerosis in a state where Cannabis is legal	Laura J Weinkle Disclosure: Dr. Weinkle has nothing to disclose.
5:30 PM	420	Screening of cognitive impairment in patients with multiple sclerosis (MS): the BICAMS short version for patient-centered care in small neurological institutions	Iris-Katharina Penner Disclosure: Dr. Penner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adamas Pharma, Almirall, Bayer Pharma, Biogen, Celgene, Desitin, Genzyme, Merck, Novartis, Roche, and Teva.
5:30 PM	421	A new electronic and brief neuropsychological scale to detect cognitive impairment (CI) in patients with multiple sclerosis (MS): Validation study of the MS-COG-e scale	José Meca Lallana Disclosure: Dr. Meca Lallana has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with J. Meca-Lallana has received consulting or speaking fees from Almirall, Biogen, Genzyme, Merck Serono, Novartis, Roche and Teva..
5:30 PM	422	Effects of Live-Online Education on Multiple Sclerosis Disease Management: Changes in Patient Experience, Clinical Practice, Provider Knowledge and Competence	Anne Roc, PhD Disclosure: Dr. Roc has nothing to disclose.
5:30 PM	423	Cognitive reserve is consistently related to cognitive performance in Multiple Sclerosis	Alvino Bisecco Disclosure: Dr. Bisecco has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Merck.
5:30 PM	424	Impact of Multiple Sclerosis on Employment and its Association with Anxiety, Depression, Fatigue and Sleep Disorders	Edgar Carnero Contentti Disclosure: Dr. Carnero has nothing to disclose.
5:30 PM	425	NA	NA NA Disclosure:
5:30 PM	426	NA	NA NA Disclosure:
5:30 PM	427	NA	NA NA Disclosure:
5:30 PM	428	NA	NA NA Disclosure:
Neuropathy II
Start Time	Pub.	Title	Presenter
5:30 PM	429	Skin coldness and painful cold: the common symptom in patients with clinically suspected small fiber neuropathy in Korea	Eun Bin Cho, MD Disclosure: Dr. Cho has nothing to disclose.
5:30 PM	430	Is There A Relationship Between Exacerbated Diabetic Peripheral Neuropathy And Metformin?	Mohammed El-Sherif, MD Disclosure: Dr. El-Sherif has nothing to disclose.
5:30 PM	431	Brachial plexopathy after influenza vaccination in adults in the USA. A report from the CDC/FDA Vaccine Adverse Event Reporting System (1990-2017)	Shreya Shah Disclosure: Dr. Shah has nothing to disclose.
5:30 PM	432	Neuropathy with Dysarthria and Ophthalmoparesis	Tekalign Burka, MD Disclosure: Dr. Burka has nothing to disclose.
5:30 PM	433	Use of Intravenous Immunoglobulin in Small Fiber Neuropathy associated with FGFR3	Ajal Dave, MD Disclosure: Dr. Dave has nothing to disclose.
5:30 PM	434	Isolated external ophthalmoplegia associated with IgG anti-GQ1b antibody	Sunhee Kim, MD Disclosure: Dr. Kim has nothing to disclose.
5:30 PM	435	A case of remission from multifocal motor neuropathy following rituximab	Natalia Gonzalez, MD Disclosure: Dr. Gonzalez has nothing to disclose.
5:30 PM	436	Late Onset TTR-related Familial Amyloid Polyneuropathy (FAP) in Two Patients with Acquired Demyelinating Features	Nazila Rad, MD Disclosure: Dr. Rad has nothing to disclose.
5:30 PM	437	A Novel Report of Nivolumab-Induced Parsonage-Turner Syndrome Associated with Hourglass-like Constriction of the Anterior Interosseous Nerve	Michael Porambo Disclosure: Dr. Porambo has nothing to disclose.
5:30 PM	438	Acute Intermittent Porphyria: Sometimes DIfficult to Diagnose	Yuri Macedo, MD Disclosure: Dr. Macedo has nothing to disclose.
5:30 PM	439	Ganglioside Antibodies in Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) and its Variants	Mithila Fadia, MBBS Disclosure: Dr. Fadia has nothing to disclose.
5:30 PM	440	Cognitive Biases at Bedside Resulting in Diagnostic Error of Guillain-Barré Syndrome	Rohit Gummi Disclosure: Dr. Gummi has nothing to disclose.
5:30 PM	441	Heterozygous Mutations of SH3TC2 as a Cause of HNPP	Devin Prior, MD Disclosure: Dr. Prior has nothing to disclose.
5:30 PM	442	Reduction in Idiopathic Peripheral Neuropathy Diagnoses Using a Comprehensive EMR-based Laboratory Order Set	Fang Bai, MD Disclosure: Dr. Bai has nothing to disclose.
5:30 PM	443	Brachial Plexopathy Post Transcatheter Arterial Chemoembolization	Kavneet Kaur, MD Disclosure: Dr. Kaur has nothing to disclose.
5:30 PM	444	Novel Mutation in KIF5A Causing Hereditary Spastic Paraplegia with Axonal Sensorimotor Neuropathy	Mathieu Cuchanski, DO Disclosure: Dr. Cuchanski has nothing to disclose.
5:30 PM	445	Eosinophilic Vasculitic Neuropathy As A Presentation Of Churg-Strauss Syndrome	Sandeep Devarapalli, MD Disclosure: Dr. Devarapalli has nothing to disclose.
5:30 PM	446	Outcome comparison of mechanically ventilated Guillain-Barre Syndrome versus Myasthenia Gravis in US Hospitals	Anantha Vellipuram Disclosure: Dr. Vellipuram has nothing to disclose.
5:30 PM	447	Guillain-Barre Syndrome as a Rare Initial Presentation of Systemic Lupus Erythematosus.	Swathy Chandrashekhar, MD Disclosure: Dr. Chandrashekhar has nothing to disclose.
5:30 PM	448	Rapidly Progressive POEMS Syndrome with Absent M protein in Serum or Urine, Normal Bone Survey, and Normal Non-targeted Bone Marrow Biopsy	Payam Soltanzadeh, MD Disclosure: Dr. Soltanzadeh has nothing to disclose.
5:30 PM	449	Modifying Hyperglycemic Peripheral Nerve Injury	Mark Stecker, MD Disclosure: Dr. Stecker has received royalty, license fees, or contractual rights payments from UPTODate.
5:30 PM	450	Rare Case of Ulnar Neuropathy	Anai Hamasaki, MD Disclosure: Dr. Hamasaki has nothing to disclose.
5:30 PM	451	Ustekinumab related CIDP in a patient with psoriatic arthritis	Gamaleldin Osman, MD Disclosure: Dr. Osman has nothing to disclose.
5:30 PM	452	Proximal Motor Sensory Hereditary Neuropathy (HMSN-P) in a Peruvian Family with Japanese Ancestry	Elison Sarapura-Castro, MD Disclosure: Dr. Sarapura Castro has nothing to disclose.
5:30 PM	453	Acute Motor Axonal Neuropathy (AMAN) presenting with truncal and appendicular ataxia	Ashmanie Mahatoo, MD Disclosure: Dr. Mahatoo has nothing to disclose.
Neuromuscular Diagnostics, Genetics, and Biomarkers
Start Time	Pub.	Title	Presenter
5:30 PM	454	Needle Impedance-Electromyography (I-EMG): a New Technique for the Electrodiagnostic Laboratory	Seward Rutkove, MD Disclosure: Dr. Rutkove has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Myolex, Biogen, Axcella Health, Merck. Dr. Rutkove has received personal compensation in an editorial capacity for Annals of Neurology. Dr. Rutkove has received compensation for serving on the Board of Directors of Myolex, Inc. Dr. Rutkove holds stock and/or stock options in Myolex, Inc which sponsored research in which Dr. Rutkove was involved as an investigator. . Dr. Rutkove holds stock and/or stock options in Myolex, Inc. Dr. Rutkove has received research support from Flex-Pharma, Inc.
5:30 PM	455	Feasibility and Validation of Modified Oculobulbar Facial Respiratory Score (mOBFRS) in Amyotrophic Lateral Sclerosis	Marie Wencel, CCRP Disclosure: Dr. Wencel has nothing to disclose.
5:30 PM	456	A New Method to Detect Potential Causative Genes for Spastic Paraplegia Utilizing Aggregate Data of Whole Exome Sequencing	Masaki Tanaka Disclosure: Dr. Tanaka has nothing to disclose.
5:30 PM	457	Smart Somatotopic Quantitative Sensory Testing findings in hATTR with Polyneuropathy	Marcus Vinicius Pinto Disclosure: Dr. Pinto has nothing to disclose.
5:30 PM	458	Genetics in patients with hereditary neuropathy	Ernesto Alonso-Labori, MD Disclosure: Dr. Alonso-Labori has nothing to disclose.
5:30 PM	459	Correlation of supranormal sensory nerve action potential amplitudes (supraSNAPs) with sensory nerve "hyperexcitable" symptoms	Philip Tipton, MD Disclosure: Dr. Tipton has nothing to disclose.
5:30 PM	460	The Role of Needle Electromyography in the Evaluation of Carpal Tunnel Syndrome	Cory Kogelschatz, MD Disclosure: Dr. Kogelschatz has nothing to disclose.
5:30 PM	461	Morphometry of dorsal rootlets using immunofluorescent confocal microscopy	Adam Loavenbruck, MD Disclosure: Dr. Loavenbruck has nothing to disclose.
5:30 PM	462	Utility of Neuromuscular Ultrasound in the Evaluation of Proximal Median Neuropathies: A Case Series	Elina Zakin Disclosure: Dr. Zakin has nothing to disclose.
5:30 PM	463	Why do we repeat electrodiagnostic studies? And, does it make a difference?	Shivakrishna Kovi Disclosure: Dr. Kovi has nothing to disclose.
5:30 PM	464	Ultrasound Guided Open Muscle Biopsy	Shumaila Sultan, MD Disclosure: Dr. Sultan has nothing to disclose.
5:30 PM	465	Clinic and Lab Based Respiratory Testing in Patients with Myasthenia Gravis	Hans Katzberg, MD Disclosure: Dr. Katzberg has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with CSL Behring, Amazentis, Flexpharma, Momenta, Octapharma, Terumo, Grifols, Genzyme. Dr. Katzberg has received research support from CSL Behring, Octapharma and Grifols.
5:30 PM	466	Comparison of Train of Four with Repetitive Nerve Stimulation in the ICU	Omer Suhaib, MD, MBBS Disclosure: Dr. Suhaib has nothing to disclose.
5:30 PM	467	Should We Refer Patients with Pain for Electromyography?	Shivkumar Bhadola Disclosure: Dr. Bhadola has nothing to disclose.
Medical Student Essay Award Recipients
Start Time	Pub.	Title	Presenter
5:30 PM	468	Functional neurological disorders in Parkinson disease	Benjamin Wissel Disclosure:
5:30 PM	469	Ghost in the Machine: Historical Aspects of Irreversible Brain Injury and Brain Death	Yi Tong Disclosure: Dr. Tong has nothing to disclose.
5:30 PM	470	Discovery of novel recessive genes in a consanguineous cohort using genotype-phenotype correlations	Kristen Martin Disclosure: Dr Martin has nothing to disclose.

Ready to register for the 2019 AAN Annual Meeting?

Related Courses

Saturday May 4, 2019
7:00 AM-9:00 AM
C1 - What Do I Do Now?: Assessment and Management of Neuropsychiatric Symptoms in Neurocognitive Disorders Daniel Kaufer MD, FAAN
C3 - Clinical EEG: Normal EEG, Normal Variants, and How to Avoid The Common Pitfall of Over-reading Selim Benbadis MD, FAAN
C4 - Pediatric Neuro-ophthalmology Update Christopher Glisson DO, FAAN
C6 - Therapy of Movement Disorders: A Case-based Approach David Riley MD
C8 - Cognitive Psychology of Neurologic Errors: Why Do Neurologists Make Errors? Louis Caplan MD, FAAN
7:00 AM-12:30 PM
C9 - Clerkship and Program Directors Conference: Let’s Build an Educational Scholarly Product Zachary London MD, FAAN
9:30 AM-11:30 AM
C12 - Clinical Approach to Muscle Disease I: Role of Antibodies, Muscle Imaging, and Genetic Testing Tahseen Mozaffar MD, FAAN
C13 - Clinicopathological Correlation Session in Dementia David Irwin MD
C14 - Child Neurology: Headache Amy Gelfand MD
C15 - Clinical EEG: Focal, Diffuse, and Epileptiform Abnormalities in Adults Katherine Noe MD, PhD, FAAN
C16 - Cerebrovascular Disease I: Prevention Larry Goldstein MD, FAAN, FAHA
C18 - Cerebellar and Afferent Ataxias: Diagnosis and Management Massimo Pandolfo MD, FAAN
C19 - Multiple Sclerosis Overview I: Clinical Pearls Mary Willis MD
12:00 PM-4:00 PM
C22 - Resident Basic Science I: Neuropathology J. Clay Goodman MD, FAAN
C23 - Skills Workshop: Neuro-ophthalmology and Neurovestibular Exam Lab (Registration Required) Matthew Thurtell MD
12:00 PM-5:00 PM
Futures in Neurological Research Boot Camp
1:00 PM-1:45 PM
Mind-body Approaches to Chronic Pain Jinny Tavee MD
1:30 PM-3:30 PM
C25 - Clinical Approach to Muscle Disease II: Inflammatory Myopathies and Muscle Pathology Tahseen Mozaffar MD, FAAN
C26 - Clinical EEG: Neonatal and Pediatric Nicholas Abend MD
C27 - Cerebrovascular Disease II: Update on Guidance-Based Diagnosis and Management of Hemorrhagic Stroke Andrew Naidech MD, FAAN
C34 - Evaluating Tremor in the Office Andres Deik Acosta Madiedo MD
C29 - Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
C32 - The Neurology of Social Behavior Bradford Dickerson MD
1:30 PM-4:00 PM
C35 - Educators' Leadership Program (Registration Required) Jaffar Khan MD, FAAN
2:30 PM-3:15 PM
Nutrition, Lifestyle, and Neuropathic Pain Julie Rowin MD, FAAN
4:00 PM-4:45 PM
Opiods: What Is Your State Doing to Confront This Epidemic? Donn Dexter MD, FAAN

Sunday May 5, 2019
7:00 AM-9:00 AM
C46 - Actualización en Dolor de Cabeza y Trastornos Neuromusculares (Update: Headache and Neuromuscular Disorder) Jose Merino MD, MPhil, FAAN, Dario Beltran MD, FAAN
C36 - Mastering EMG Waveform Recognition Skills in Just Two Hours! Devon Rubin MD, FAAN
C37 - Chronic Traumatic Encephalopathy: Update Andrew Budson MD
C39 - Introduction to Clinical Research and Methods Laurie Gutmann MD, FAAN
C40 - Child Neurology: Stroke Lori Billinghurst MD
C42 - The Dystonias: Diagnosis, Treatment and Update on Etiologies Rachel Saunders-Pullman MD
C44 - Multiple Sclerosis Therapy: Symptom Management Andrew Solomon MD
C45 - Status Epilepticus Stephan Schuele MD, FAAN
8:00 AM-8:30 AM
Top Ten Clinical, Educational, and Leadership Pearls Steven Galetta MD, FAAN
9:15 AM-12:00 PM
Presidential Plenary Session Natalia Rost MD, MPH, FAAN, FAHA
12:30 PM-5:30 PM
Medical Student Symposium
1:00 PM-3:00 PM
C60 - Assessment of Rapidly Progressive Dementias I: Prion and Non-prion Neurodegenerative Diseases Michael Geschwind MD, PhD, FAAN
C49 - Neurology Update I: Mutiple Sclerosis, Sleep, and Neuromuscular Disease Ralph Jozefowicz MD, FAAN, Adam Quick MD
C50 - Cerebrovascular Disease III: Update on Neuroimaging Modalities and Endovascular Therapies for Acute Ischemic Stroke Johanna Fifi MD
C51 - Balance and Gait Disorders Alfonso Fasano MD, PhD
C54 - Neuro-otology: The Common Peripheral Vestibular Disorders Kevin Kerber MD
C56 - Multiple Sclerosis Therapy: Disease-modifying Treatment I Scott Newsome DO, FAAN
C47 - Evaluation and Management of Autonomic Disorders I: Autonomic Testing, Failure, and Peripheral Neuropathies Amanda Peltier MD, MS
S3 - Epilepsy/Clinical Neurophysiology (EEG)
S5 - Neuromuscular and Clinical Neurophysiology (EMG)
S4 - Movement Disorders
S6 - MS and CNS Inflammatory Disease
1:00 PM-5:30 PM
C64 - Skills Workshop: Neurophysiologic Intraoperative Monitoring (Registration Required) Aatif Husain MD
C63 - Resident Basic Science II: Neuropharmacology James Owens MD, PhD
2:00 PM-2:45 PM
Navigating a Career in Academics Joseph Safdieh MD, FAAN, Jennifer Molano MD, FAAN
3:00 PM-3:45 PM
Practice Innovation in Epilepsy Anup Patel MD, FAAN
3:30 PM-5:30 PM
C77 - Assessment of Rapidly Progressive Dementias II: Infections and Autoimmune Mediated Conditions Michael Geschwind MD, PhD, FAAN
C67 - Neurology Update II: Behavioral Neurology, Movement Disorders, and Neuro-ophthalmology Ralph Jozefowicz MD, FAAN, Adam Quick MD
C68 - Cerebrovascular Disease IV: Telestroke Eric Anderson MD, PhD
C69 - The Palliative Care Guide in Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Life-limiting Neurological Disorders Tobias Walbert MD, PhD
C71 - Neuro-otology: Diagnosis and Treatment of Nuanced Causes of Dizziness Kevin Kerber MD
C72 - Disordered Sleep in Common Neurologic Diseases: Traumatic Brain Injury, Stroke, and Parkinson’s Disease LynnMarie Trotti MD
C73 - Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
C65 - Evaluation and Management of Autonomic Disorders II: Diagnostic Approach and Treatments for Dysautonomia Amanda Peltier MD, MS
N1 - Neuroscience in the Clinic: Child Neurology: Movement Disorders Deborah Hall MD, PhD, FAAN, Erika Augustine MD, FAAN
C76 - Actualización en Lesión Cerebral Traumática e Ictus Isquémico (Update: TBI and Stroke) Jose Merino MD, MPhil, FAAN, Dario Beltran MD, FAAN
S9 - Aging, Dementia, Cognitive, and Behavioral Neurology
S10 - Movement Disorders
3:45 PM-4:30 PM
Introduction to Acupuncture II - Evidence-based Applications for Acupuncture in the Treatment of Painful Neurologic Conditions Alexandra Dimitrova MD
4:00 PM-4:45 PM
A "How to and Why" of the Shared Medical Appointments: A Way to Meet the Needs of the Patient and Provider While Maximizing Clinical Time Mary Rensel MD, FAAN
Work Life Balance in Research and Academics Amanda Peltier MD, MS

Monday May 6, 2019
7:00 AM-9:00 AM
C78 - Addiction Mishka Terplan MD, MPH
C79 - Atypical and Young-onset Dementias Jonathan Graff-Radford MD
C81 - Epileptologists’ Secrets for the Busy General Neurologist: Localization, Imaging, and Fear of Surgery Carol Ulloa MD
C83 - Stroke in Young Adults and Women Aneesh Singhal MD, FAAN
C84 - Diagnosis and Treatment of Functional Movement Disorders Mark Hallett MD, FAAN
C86 - Severe TBI: From ICU to Rehabilitation Susanne Muehlschlegel MD, MPH
C87 - Neuromyelitis Optica Spectrum Disorders Dean Wingerchuk MD, FAAN
C88 - Skills Workshop: Clinical Usefulness of Botulinum Toxin for Spasticity (Registration Required) Allison Brashear MD, MBA, FAAN
8:00 AM-8:45 AM
Physical Exercise and Cognitive Training in Neurology-Application in Aging & Neurodegenerative Disease Ergun Uc MD
11:45 AM-12:30 PM
Self Management in Neurologic Disease Barbara Jobst MD, FAAN, Lisa Shulman MD, FAAN
1:00 PM-3:00 PM
C89 - Mild Cognitive Impairment: Implications for Clinicians Ronald Petersen PhD, MD, FAAN
C102 - Clinical EMG I: Principles and Practice of NCS and Needle EMG Ruple Laughlin MD, FAAN
C91 - Clinical Epilepsy I: Basics Tracey Milligan MD, FAAN
C92 - Neurology Update III: Headache, Neuro-otology, and Epilepsy Ralph Jozefowicz MD, FAAN, Adam Quick MD
C93 - Autism Spectrum Disorders What We Know and Where We Are Going Rujuta Wilson MD
C94 - Paroxysmal Movement Disorders Kailash Bhatia MD, FAAN
C95 - Now You See It, Now You Know It: Pathognomonic Neuro-ophthalmology Examination Findings Eric Eggenberger DO, FAAN
C99 - Faculty Development: Enhancing Your Role in Student and Resident Training Vicki Shanker MD
C101 - Esclerosis Múltiple y Otras Enfermedades Inflamatorias Desmielinizantes y Autoinmunes del Sistema Nervioso Central (MS and Other Demyelinating Inflammatory and Autoimmune Central Nervous System Disorders) Lilyana Amezcua MD
S12 - MS and CNS Inflammatory Disease
S13 - Behavioral and Cognitive Neurology
S15 - Cerebrovascular Disease and Interventional Neurology
S16 - Movement Disorders
1:00 PM-5:30 PM
C104 - Resident Basic Science III: Neuroanatomy: All the Lesions Zachary London MD, FAAN
C106 - Skills Workshop: Clinical Uses of Botulinum Toxin for Dystonia (Registration Required) Diego Torres-Russotto MD, FAAN
C105 - Research Career Symposium Chad Hales MD, PhD
2:30 PM-3:15 PM
The Role of Integrative Medicine in Epilepsy Ann Marie Collier MD
3:30 PM-4:45 PM
S18 - Autonomic Disorders
3:30 PM-5:30 PM
C120 - Clinical EMG II: Case-based Clinical Applications of Nerve Conduction Studies and Needle Electromyography Ruple Laughlin MD, FAAN
C107 - Cognitive Impairment Due to Alzheimer's Disease: Using Old Skills and New Tools for Diagnosis and Treatment David Knopman MD, FAAN
C108 - Emergency Room Neuro-ophthalmology Heather Moss MD, PhD, FAAN
C109 - Clinical Epilepsy II: Considerations Across the Age Span: Pediatrics, Pregnancy, and Elderly Barbara Jobst MD, FAAN
C110 - Neurology Update IV: Stroke, Neuro-infectious Disease, and Autoimmune Encephalopathies Ralph Jozefowicz MD, FAAN, Adam Quick MD
C118 - Tourette Syndrome: Assessment and Management Tamara Pringsheim MD, FAAN
S19 - Child Neurology and Developmental Neurology
S22 - Cerebrovascular Disease and Interventional Neurology
S23 - Neuromuscular and Clinical Neurophysiology (EMG)
5:00 PM-5:45 PM
Defining, Evaluating, and Promoting Healthy Cognitive Aging Kirk Daffner MD, FAAN

Tuesday May 7, 2019
7:00 AM-9:00 AM
C121 - Clinical EMG III: Nerve Conduction Criteria and Electrodiagnostic Approaches Mark Bromberg MD, PhD, FAAN
C123 - Child Neurology: Genetic and Metabolic Testing in Pediatric Epilepsy James Riviello MD
C122 - Neurocognitive Assessment for Neurologists Mario Mendez MD, PhD, FAAN
C124 - Endovascular Treatment of Acute Stroke and Cerebrovascular Disease Dileep Yavagal MD, FAAN
C126 - Active Management of Professionalism Lapses: A New Way of Thinking Ann Poncelet MD, FAAN
C127 - Hyperkinetic Movement Disorders: Videodiagnosis and Treatment Steven Frucht MD
C128 - Neck Pain, Cervical Spinal Stenosis, Cervical Radiculopathy, and Cervical Spondylotic Myelopathy John Engstrom MD, FAAN
C130 - Diagnostic Pearls in Myelitis: a Case-based Approach Eoin Flanagan MBBCh
11:45 AM-12:30 PM
Treatment of Neuopathy Symptoms without Medication Janice Wiesman MD, FAAN
1:00 PM-1:45 PM
Virtual Reality for Chronic Pain Mary Catherine George PhD
1:00 PM-2:00 PM
S24 - Pain and Palliative Care
1:00 PM-3:00 PM
C132 - Frontotemporal Dementias Elizabeth Finger MD, FAAN
C131 - Small Fiber Neuropathies: Sensory, Autonomic, and Both I: Focus on Autonomic Nervous System Christopher Gibbons MD, FAAN
C133 - Clinical Epilepsy III: Advanced (Status, Beyond AED, Video EEG) Tobias Loddenkemper MD
C135 - Case Studies: Challenging Acute Ischemic Stroke Cases Vivien Lee MD, FAAN
C137 - Deep Brain Stimulation I: Basic Principles and Programming in Movement Disorders Michael Pourfar MD
C139 - Eye Movement Disorders: A Systematic Approach to the Evaluation of Diplopia Janet Rucker MD
C143 - Education Research Methodology Course Andrew Southerland MD
S25 - Child Neurology and Developmental Neurology
S26 - MS and CNS Inflammatory Disease
1:00 PM-5:30 PM
C148 - Skills Workshop: EMG: Basic (Registration Required) Holli Horak MD, FAAN
2:00 PM-2:45 PM
The HSR Game Show Jason Sico MD, FAAN, Gregory Esper MD, MBA, FAAN
2:15 PM-3:30 PM
Treating Pain with Herbs, Supplements, and Marijuana Ilene Ruhoy MD
3:30 PM-4:15 PM
S28 - Neuro-ophthalmology/Neuro-otology
3:30 PM-5:30 PM
C150 - Small Fiber Neuropathies: Sensory, Autonomic, and Both II: Focus on Sensory Nervous System Christopher Gibbons MD, FAAN
C151 - Lewy Body Dementias Karen Marder MD, MPH, FAAN
C164 - Update on Medical Management of Stroke Adam De Havenon MD
C155 - Deep Brain Stimulation II: Advanced Management in Movement Disorders and Applications Beyond Movement Disorders Leonard Verhagen Metman MD, PhD
C157 - Evaluation and Treatment of Common Spine Disorders J. D. Bartleson MD, FAAN
C159 - Mid-Level Faculty Career Development Course Deborah Hall MD, PhD, FAAN
C161 - Child Neurology: Metabolic Marc Patterson MD, FAAN, FRACP
C152 - Clinical Epilepsy IV: Surgery Gregory Cascino MD, FAAN
S31 - MS and CNS Inflammatory Disease

Wednesday May 8, 2019
7:00 AM-7:45 AM
Simulation in Neurology Education Aaron Nelson MD, Ariane Lewis MD, Arielle Kurzweil MD
7:00 AM-9:00 AM
C165 - Current Management of Incidental and Asymptomatic Cerebrovascular Lesions Robert Brown MD, FAAN
C166 - Neuroimaging Biomarkers Across the Dementia Spectrum Liana Apostolova MD, FAAN
C167 - Lumbar Radiculopathy, Lumbar Spinal Stenosis, Low Back Pain, and Failed Back Syndrome Ligia Onofrei MD
C168 - Parkinson's Disease Update Melissa Nirenberg MD, PhD, FAAN
C174 - Neuro-ophthalmology I: Visual Loss, Optic Neuropathies, and Papilledema Nancy Newman MD, FAAN
C170 - Video EEG: Name That Spell Amy Crepeau MD
C171 - Child Neurology: Neuromuscular/Autoimmune Neurology Anne Connolly MD, FAAN
C173 - Skills Workshop: Practical Training in Injection Techniques in the Treatment of Headache Disorders (Registration Required) Amaal Starling MD, Rashmi Halker MD
8:00 AM-8:45 AM
Complementary Therapies in Parkinson's Disease Veronica Santini MD
9:15 AM-11:30 AM
Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C175 - Neuromuscular Junction Disorders I: Myasthenia Gravis, Ocular, and MuSK Myasthenia Laura Tormoehlen MD, FAAN
C176 - Behavioral Neurology I: Network Anatomy of Behavior and Language Maria Gorno Tempini MD, PhD
C177 - Maximizing Quality of Life in Stroke, ALS, Parkinson’s Disease, and Dementia: A Palliative Approach Maisha Robinson MD, MS
C179 - Nonmotor Manifestations of Parkinson's Disease I Jennifer Goldman MD, MS, FAAN
C188 - Neuro-ophthalmology II: Optic Neuritis, Visual Fields, and Anisocoria Nancy Newman MD, FAAN
C181 - Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN
C183 - Reading, Critiquing, and Reviewing the Neurologic Literature: An Evidence-based Approach and Case-based Presentation of Peer Reviews in Neurology Roy Strowd MD
C185 - Actualización en Trastornos del Movimiento (Update in Movement Disorders) Andres Deik Acosta Madiedo MD
C186 - Women Founders of Neurology and Neuroscience I Stefano Sandrone PhD
S34 - Aging, Dementia, Cognitive, and Behavioral Neurology
S35 - Cerebrovascular Disease and Interventional Neurology
S36 - Epilepsy/Clinical Neurophysiology (EEG)
S37 - MS and CNS Inflammatory Disease
1:00 PM-5:30 PM
C190 - Skills Workshop: Neurostimulation (Registration Required) David Spencer MD, FAAN
C191 - Skills Workshop: Neuromuscular Ultrasound (Registration Required) Craig Zaidman MD
3:30 PM-5:30 PM
C192 - Neuromuscular Junction Disorders II: Toxins, Lambert-Eaton Syndrome and Less Common Disorders of Neuromuscular Transmission Laura Tormoehlen MD, FAAN
C193 - Behavioral Neurology II: Memory and Attention Maria Gorno Tempini MD, PhD
C195 - Therapy in Neurology II: Neurocritical Care and Neuromuscular Disease Madhu Soni MD, FAAN
C196 - Nonmotor Manifestations of Parkinson's Disease II Jennifer Goldman MD, MS, FAAN
C204 - Neuro-ophthalmology III: Diplopia, Ocular Motility Disorders, and Nystagmus Nancy Newman MD, FAAN
C198 - Integrating Sleep Medicine Concepts into Your Child Neurology Practice Suresh Kotagal MD, FAAN
C202 - Women Founders of Neurology and Neuroscience II Stefano Sandrone PhD
S39 - Research Methodology and Education
S40 - Cerebrovascular Disease and Interventional Neurology
S41 - Movement Disorders
S42 - Neuromuscular and Clinical Neurophysiology (EMG)
3:45 PM-4:15 PM
Update on the Complementary Therapies for MS: An Evidence-based Review Vijayshree Yadav MD, FAAN
5:00 PM-5:45 PM
Case Studies: When to Refer Patients for Cognitive Behavioral or Mindfulness Based Psychotherapies: Expanding the Neurologist’s Toolbox Gaston Baslet MD, David Perez MD, Aneeta Saxena MD

Thursday May 9, 2019
7:00 AM-9:00 AM
C205 - Peripheral Neuropathy I: Anatomical Basis and Acquired Demyelinating Neuropathies David Herrmann MD, FAAN
C206 - Vascular Cognitive Impairment and Dementia: Current Status and Future Larry Goldstein MD, FAAN, FAHA
C209 - Movement Disorders for the General Neurologist I: New Concepts in the Diagnosis and Management of Parkinson's Disease Irene Litvan MD, FAAN
C211 - Nystagmus and Saccadic Intrusions Made Simple Janet Rucker MD
C213 - Communication Skills: From Good to Great Tara Cook MD
C214 - Child Neurology: A Case-based Approach Elaine Wirrell MD, FAAN
8:00 AM-8:45 AM
Creating, Evaluating, and Publishing Your Active Learning Modules Diana Barratt MD, MPH, FAAN
11:45 AM-12:30 PM
How Your Social Life Might Be Helping (or Harming) Your Brain Joel Salinas MD
1:00 PM-2:30 PM
S44 - History of Neurology
1:00 PM-3:00 PM
C215 - Peripheral Neuropathy II: Update on Diabetic, Immune Axonal, and Hematologic-related Neuropathies Michelle Mauermann MD, FAAN
C216 - Higher Cortical Visual Disorders: Case-based Review Sashank Prasad MD
C217 - Core Concepts in Pain Management: Refractory Neuropathic Pain Practical Pharmacologics, Advances in Neuromodulation, and a Balanced Look at Cannabinoids James Watson MD
C218 - Critical Care EEG Monitoring Suzette LaRoche MD, FAAN
C219 - Therapy in Neurology III: Epilepsy and Headache David Dodick MD, FAAN
C220 - Movement Disorders for the General Neurologist II: Tremor, Drug-induced Movement Disorders, RLS, and Ataxia Joohi Jimenez Shahed MD
S47 - Cerebrovascular Disease and Interventional Neurology
S48 - Epilepsy/Clinical Neurophysiology (EEG)
S49 - MS and CNS Inflammatory Disease
3:30 PM-5:30 PM
C228 - Peripheral Neuropathy III: Genetic Neuropathies: Molecular Diagnosis and Treatment Perspectives Mario Saporta MD, PhD, FAAN
C230 - Safe and Appropriate Opioid Prescribing in Neurology Adam Burkey MD
C231 - Women With Epilepsy (WWE): Beyond Seizure Control Anne Van Cott MD, FAAN
C232 - Therapy in Neurology IV: Movement Disorders and Stroke David Dodick MD, FAAN
C233 - Movement Disorders for the General Neurologist III: Chorea, Dystonia, Myoclonus, Stereotypies, and Tics Shyamal Mehta MD, PhD
S51 - Child Neurology and Developmental Neurology
S52 - Cerebrovascular Disease and Interventional Neurology
S53 - Movement Disorders
S54 - Neuromuscular and Clinical Neurophysiology (EMG)
S55 - MS and CNS Inflammatory Disease
5:00 PM-5:45 PM
Influence of a Comprehensive Lifestyle Intervention on Prevention of Dementia A Sherzai MD, MAS, PhD(c), Ayesha Sherzai MD
7:00 PM-10:00 PM
C237 - Case Studies: Diagnosis and Management of Unusual Cases in Neuromuscular Disease Robert Pascuzzi MD, FAAN
C240 - Case Studies: Unusual Movement Disorders Kailash Bhatia MD, FAAN
C242 - Case Studies: Dementia Gregory Day MD, MSc

Friday May 10, 2019
7:00 AM-9:00 AM
C243 - Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis Michael Weiss MD, FAAN
C244 - Acute and Chronic Clinical Epilepsy Update Explained in 6 Cases Matthew Hoerth MD
C245 - Controversies in Stroke Treatment and Prevention Pierre Fayad MD, FAAN, FAHA
C246 - Hot Topics and Controversies in Parkinson's Disease Melissa Nirenberg MD, PhD, FAAN
C248 - Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
8:00 AM-8:45 AM
How to Give Effective Feedback Adnan Subei DO, Jill Liebman DO, Farah Fourcand MD, Diana Barratt MD, MPH, FAAN, Maryam Shakir MPH
1:00 PM-1:45 PM
Growing Research in Medical Marijuana Anup Patel MD, FAAN
1:00 PM-3:00 PM
C250 - Update in Epilepsy Joseph Sirven MD, FAAN
C252 - Update in Aging and Dementia Gil Rabinovici MD
C251 - Neuro-ophthalmology: Overview and Update Nancy Newman MD, FAAN
C253 - Update in Movement Disorders Alfonso Fasano MD, PhD
S56 - MS and CNS Inflammatory Disease
S57 - Cerebrovascular Disease and Interventional Neurology
S58 - Neuromuscular and Clinical Neurophysiology (EMG)
3:30 PM-4:30 PM
C254 - Education Blitz: Child Neurology: Concussion Meeryo Choe MD
C255 - Education Blitz: Normal Pressure Hydrocephalus Neill Graff-Radford MD, FAAN
C258 - Education Blitz: Multiple Sclerosis Stephen Krieger MD, FAAN

Universal Navigation

P2 - Poster Session II

Ready to register for the 2019 AAN Annual Meeting?

Related Courses

Footer